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 INTRODUCTION: 
              65% patients with head and neck tumors present with locally advanced disease. 
Concurrent chemo radiotherapy is a treatment program for locoregionally advanced squamous 
cell carcinomas of the head and neck with established benefits in both organ preservation and 
survival. 
AIMS AND OBJECTIVES: 
              To assess the immediate locoregional response rates of locally advanced squamous cell 
carcinomas of the head and neck treated with concomitant boost radiotherapy and chemotherapy 
using low dose weekly cisplatin and paclitaxel. To assess acute toxicity to the treatment.  
 
MATERIALS AND METHODOLOGY:  
                 Single arm prospective study with 30 consecutive patients with locally advanced head 
and neck cancer presented to the department of radiotherapy, Madras medical college, Chennai. 
       All patients were treated with Radiotherapy using concomitant boost 45gy/1.8gyper# /25#  
-  5 weeks ,22.5gy/ 1.5gy per# /15#  given as a boost only to small field including primary and 
involved node at an interval of 6 hrs during last 3 weeks of treatment along with weekly CDDP 
and low dose PACLITAXEL. 
RESULTS:  
             Among 30 patients, Ca Oropharynx was 9 patients, followed by Ca Hypopharynx 8 
patients, Ca Oral cavity with 5 patients and Ca Supraglottis 8 patients. 83% of patients had 
complete response and 17% had partial response. Toxicities observed in the study were 
Mucositis grade 3 in 6 patients and grade 4 in 1 patients; Skin reactions grade 3 in 2 patients.  
Leucopenia grade 1 in 4 patients grade 2 in 3 patients. There was no renal toxicity in this study. 
There was no treatment related deaths in this study. 
CONCLUSION: Concomitant Boost Irradiation with weekly low dose chemotherapy in locally 
advanced squamous cell carcinoma of head and neck cancer is better regimen with manageable 
toxicity with higher complete response. 
Keywords: concurrent chemoradiation, concomitant boost, cisplatin, paclitaxel 
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INTRODUCTION 
The term “Head and Neck cancer”   refers to neoplasms 
arising from below the base of the skull to the region of thoracic 
inlet. Majority among the head and neck malignancies arise from 
the different anatomic subsites and air spaces within this  region. 
Most of the lesions arise from the upper respiratory and digestive 
tracts. Since the Head and neck   is responsible for various 
important functions such as vision, taste, hearing, smell, 
deglutition, and breathing, various malignancies can jeopard ize 
these functions. This is also the most visible part of the individual’s 
physical appearance and therefore the cosmetic disturbance affects 
the person both mentally and physically. The management of  the 
Head and neck cancer is therefore an important aspect of oncology 
in India. 
As the life expectancy of the population rises, there is an 
increasing incidence in the trend of cancer in the world. They pose 
a significant health problem especially in developing countries, 
including India. Due to high exposure to smokeless and smoke 
tobacco among Indian people, head and neck cancers in India 
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continues to be a major public health problem and it causes 
significant morbidity and mortality. 
Head and neck region cancers represent a heterogeneous 
group of cancers arising from the mucosa of upper aerodigestive 
organs, lined by squamous epithelium. It comprises the cancers in 
the following anatomical regions, nasalcavity, nasopharynx, oral 
cavity, oropharynx, hypopharynx, the larynx, the salivary glands 
and the paranasal sinuses. 
EPIDEMIOLOGY 
The Head and neck cancers comprises 5% of all the 
malignancies worldwide.
1 
 The geographical distribution of head 
and  neck cancers varies significantly among different parts of the 
world. In western Europe and USA the incidence is relatively low. 
The incidence is high in the countries of South East Asia , parts of 
Africa and South America. The overall male to female ratio is 4;1. 
It usually occurs in the 5
th
 decade and above, except for salivary 
gland tumours and nasopharyngeal tumours which tend to occur 
commonly in younger age group. 
GLOBAL INCIDENCE 
Overall, head and neck cancer constitutes more than 550,000 
cases annually worldwide.
2
 Head and neck cancer incidence is 
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about 3% of all cancers in the United States. In the current  year, 
approximately 59,340 people (43,390 men and 15,950 women) will 
develop head and neck cancer. It is also calculated that 12,290 
deaths (8,900 men and 3,390 women) will occur this year.  The  
laryngeal cancer incidence is , but not oral cavity and pharyngeal 
cancer, is approximately 50 percent higher in African American 
men. To draw the world’s attention on effective care and control on 
head and neck cancer,  the International Federation of Head and 
Neck Oncologic Society proposed 27th July as the World Head 
and Neck Cancer Day. 
INDIAN SCENARIO 
 Head and Neck Cancer is one of the leading cause of death 
and disability in India, while oral cancer is the most common 
malignancy of all head and neck cancers and is the primary cause of 
cancer related deaths in India in men. India has an increase in the 
incidence of head and neck cancers. Infact, they are among the top 
cancers affecting men and are the third most common cancers 
affecting women. Since 90% of these tumours are related to risk 
factors such as tobacco, alcohol and areca-nut usage, they are 
highly preventable. 
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TAMILNADU SCENARIO 
 In southern India, the common cancers among male were 
found to be stomach, oral, esophagus and leukemia whereas females 
were mainly affected by cervix, breast, oral and esophageal 
cancers. In Tamilnadu, MMTR states that most common cancer in 
men is head and neck cancer (19.23%) followed next  by stomach 
cancer (13.98%) and  lung cancer (12.46%). In women, breast 
cancer is the most common (20.87%) followed by cervical cancer 
(11.46%), stomach cancer (8.11%) and head and neck cancer 
(7.53%). 
In our institute Barnard Institute of Radiology & Oncology, 
head and neck cancers constitute the majority of cases registered in 
our OPD. Majority of them are squamous cell carcinomas (~95%) 
with other histologies making up the remaining. Nearly 75% of 
them present in the locally advanced stage. Only around 20 to 25% 
of the cases present in the early stages. Most of them belong to 
poor socioeconomic status, tobacco users either in smoked form 
such as cigarettes, beedis or non-smoked forms such as pan etc. 
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RISK FACTORS 
TOBACCO 
Tobacco use remains one of the leading causes of death 
worldwide. Data from the Global Adult Tobacco Survey (GATS),  
which conducted representative household surveys in 14 low- and 
middle-income countries such as Bangladesh, Brazil, China, Egypt, 
India, Mexico, Philippines, Poland, Russia, Thailand, Turkey, 
Ukraine, Uruguay, and Vietnam), suggest 41% of men and 5% of 
women across these countries currently smoke.
 3  
 Among youth,  
there is some evidence of growth in use of other forms of tobacco 
(e.g., cigars, water pipes, electronic cigarettes) in 2011 to 2012 that 
may be displacing cigarette use.
4
  
A common index of cancer risk is pack-years, or the number 
of packs of cigarettes smoked per day multiplied by the number of 
years smoked in the lifetime. In general, the higher the number of 
pack-years, the greater the cancer risk. The level of tobacco 
exposure is ultimately driven by use behaviors, including the 
number of cigarettes smoked, the patterns of smoking on individual 
cigarettes, and the number of years smoked. The primary driver of 
smoking behavior is nicotine,  the major addictive substance and 
primary reinforcer of continued smoking. Nicotine is metabolized 
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primarily to cotinine, which is further metabolized to trans-3â€²-
hydroxycotinine (3HC), catalyzed by the liver cytochrome P450 
2A6 enzyme. The ratio of 3HC to cotinine in plasma or saliva can 
be used as a reliable noninvasive phenotypic marker for CYP2A6 
activity. CYP2A6 activity is known to vary across racial/ethnic 
groups, with those of African or Asian descent showing slower 
metabolism than those of Caucasian descent.
5
 In these analyses, the 
N-nitrosamines, benzene, 1,3-butadiene, aromatic amines, and 
cadmium often rank highly.  Smokeless products available in India 
are often far higher in nitrosamines. PAH and nitrosamines are also 
likely to be implicated in cancers along the respiratory tract and the 
cervix. Smoke carcinogens are known to cause G:A and G:T 
mutations, and mutations in the KRAS oncogene and the P53 tumor 
suppressor gene are strongly associated with tobacco-caused 
cancers.
6
   
SMOKELESS TOBACCO 
Globally there is a 60% increase in alternative nicotine 
delivery systems like snuff, lozenges. Betel quid is extensively used 
in India. It is also called aspan which consists of pieces of areca 
nut, tobacco and slaked lime. Added to this are 
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spices,cardamom,cloves,according to the localpreferences and are 
varyingly called as gutkha, zarda, mawa, khaini. 
HUMAN PAPILLOMA VIRUSES 
Viral infections are estimated to play a causal role in at least 
11% of all new cancer diagnoses worldwide. A vast majority of 
cases (>85%) occur in developing countries, where poor sanitation, 
high rates of cocarcinogenic factors such as HIV/AIDS, and lack of 
access to vaccines and cancer screening all contribute to increased 
rates of virally induced cancers. A common feature of DNA viruses 
that depend on host cell DNA polymerases for replication (e.g., 
papillomaviruses, herpesviruses, and polyomaviruses) is the 
expression of viral gene products that promote progression into the 
cell cycle. A typical mechanism of direct oncogenic effects is 
through the inactivation of tumor suppressor proteins, such as 
the guardian of the genome, p53, and retinoblastoma protein (pRB). 
This effectively primes the cell to express the host machinery 
necessary for replicating the viral DNA. 
Many of the tumors found in nonsmokers were found to have 
wild-type p53 genes, raising the possibility that the tumor might be 
dependent on a p53-suppressing viral oncogene (as seen in cervical 
cancer). Gillison and colleagues went on to show that nearly half of 
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all tonsillar cancers contain HPV DNA, most commonly HPV16. 
Interestingly, HPV-positive oropharyngeal cancers tend to be less 
lethal than tobacco-associated HPV-negative tumors. This finding 
has important considerations for treatment of HPV-positive head 
and neck cancers.
7
 Recent studies suggest an ongoing increase in 
the incidence of HPV-associated cancers of the tonsils and the base 
of the tongue. By 2025, the number of new HPV-induced head and 
neck cancer cases in the United States is expected to roughly equal 
the number of new cervical cancer cases.  Based in part on these 
observations, the U.S. Centers for Disease Control and Prevention 
recommends that boys, in addition to girls, should be vaccinated 
against high-risk HPVs. 
HPV-positive oropharyngeal cancers show improved response 
to therapy when compared to HPV-negative cancers of the same 
site.
8 
 Patients presenting with HPV-positive oropharyngeal cancers 
also tend to be younger, healthier, and have a much lower 
frequency of smoking and alcohol abuse. However, some studies 
have shown that a history of smoking in patients with HPV-positive 
oropharyngeal cancer may increase the likelihood of recurrence or 
metastasis after treatment. This has prompted many to consider 
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reducing the intensity of treatment to decrease treatment-related 
morbidity. 
GENETIC FACTORS 
  The genes associated with an inherited predisposition to 
head and neck cancer include the master regulator, TP53 (Li-
Fraumeni syndrome),
 
 and Fanconi anemia genes, the FANC family 
of DNA repair genes that are inturn associated with the 
development of HNSCC.
9 
  Head and neck cancers arising in young 
patients and others that are independent of tobacco exposure 
provide a rich area for an in-depth molecular assessment to 
determine the underlying genetic factors.  
OTHER FACTORS 
 The effects of alcohol and tobacco seems to be additive. It 
might also mediate through common malnutrition and vitamin 
deficiency. Alcohol intake increases the risk by 2 to 6 fold.  
  The inhalation of dusts and chemical constituents give rise 
to cancer of nasal cavity and paranasal sinuses. Occupational 
exposure to wood dust, textile fiber, nickel and radium also 
predispose to cancer. 
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 Low socioeconomic status leading to improper nutrition and 
poor vitamin intake are associated with higher risk of head and 
neck cancer. It is known that vitamins such as Retinoic acid are 
important in preventing the occurrence of cancer in the upper 
aerodigestive tract. Other factors include poor orodental hygiene, ill 
fitting dentures etc. 
 HISTOPATHOLOGY 
 Most head and neck malignant neoplasms arise from the 
surface epithelium and are squamous cell carcinoma (SCC) or one 
of its variants, including lymphoepithelioma, spindle cell 
carcinoma, verrucous carcinoma, and undifferentiated carcinoma. 
Lymphomas and a wide variety of other malignant and benign 
neoplasms make up the remaining cases. Head and neck squamous 
cell carcinoma (HNSCC) accounts for 90% of all malignant disease 
in the head and neck region of the body. 
Lymphoepithelioma is an SCC with a lymphoid stroma and 
occurs in the nasopharynx, tonsillar fossa, and base of tongue; it 
may also occur in the salivary glands. In the spindle cell variant, 
there is a spindle cell component that resembles sarcoma 
intermixed with SCC. It is generally managed like other high-grade 
SCCs.  
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Verrucous carcinoma is a low-grade SCC found most often 
in the oral cavity, particularly on the gingiva and buccal mucosa. It 
usually has an indolent growth pattern and is often associated with 
the chronic use of snuff or chewing tobacco. Small cell 
neuroendocrine carcinoma occurs rarely throughout the head and 
neck. 
CLINICAL FEATURES 
  Oral ulceration, unusual bleeding in the mouth,sore throat, 
dysphagia, hoarseness of voice, otalgia, growth in tongue, pain, 
numbness of the face,dyspnea, difficulty in speaking or opening the 
mouth and headache are the varied symptomatology at presentation.  
DIAGNOSTIC WORKUP 
 History and Physical Examination 
 Biopsy from the lesion 
 Pan Endoscopy 
 Contrast Enhanced CT scan from base of skull to root of neck or 
MRI to know the extent of the disease and involvement of 
lymphnodes. 
 CBC, RFT , LFT , BLOOD GROUPING AND TYPING  
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 Viral Markers 
 Chest X RAY 
Patients with N3 neck disease, as well as those with N2 
disease with nodes below the level of the thyroid notch, have a 20% 
to 30% risk of developing distant metastases and are considered for 
a chest CT or positron emission tomography (PET).  
PROGNOSTIC FACTORS 
  Prognosis of patients with head and neck cancers depends 
most importantly on the stage of the disease at presentation. 
Involvement of nodes in head and neck cancers upgrades it to stage 
III and also the survival of these patients is decreased by as much 
as 50 %. Involvement of regional lymph nodes and also advanced T 
stages have higher incidence of locoregional recurrences and also 
distant metastasis. They also require multimodality treatment than 
the early stage cancers in which single modality will achieve cure 
in more than 90% of cancers. Even with these aggressive 
approaches more than 50 – 60% will fail the treatment and have 
local recurrences and in the rare cases develop distant metastasis. 
Death in such cases  are usually due to locoregional recurrences. 
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TREATMENT OVERVIEW 
   Most of the cases present in locally advanced stage in 
developing countries like India because of poor socio economic 
status, illiteracy, increased use of tobacco , and inadequate 
screening and early detection. Therefore multimodality treatment is 
the best option foe treating squamous cell carcinoma of head and 
neck. The sequencing of the modalities depend on the tumour stage,  
Bulk of the disease, performance status of the patient. 
Commonly used modalities are   
1)Surgery followed by RT / ChemoRT. 
2)Chemoradiation  followed by surgery 
3)Induction chemotherapy followed by concurrent chemoRT.  
4)Defnitive  radiotherapy with targeted agents. 
SURGERY 
The advantages of surgery compared with RT, assuming 
similar cure rates, may include the following:  
1) tumour with adequate clearance is alone removed 
2) the treatment time is shorter,  
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3) the risk of immediate and late RT sequelae is avoided, and  
4) RT is reserved for a head and neck second primary tumour , 
which may not be as suitable for surgery 
Different types of surgical procedures in the treatment of 
head and neck cancers include wide local excision with adequate 
clearance, partial or total glossectomy, composite resection with 
flap reconstruction, total laryngopharyngectomy, segmental or 
marginal mandibular resection with or without mandibular 
reconstruction using fibula. Surgery remains the main modality for 
nasal cavity and paranasal tumours, major and minor salivary gland 
tumours, and thyroid malignancies whereas radiotherapy still plays 
the major role in the management of ca nasopharynx. 
NECK NODES MANAGEMENT 
The neck node dissection is of many types which depend mainly on 
the clinically positive or negative nodes, the presence of ipsilateral or 
contralateral nodes, levels of nodes involved, presence of extracapsular 
extension, the primary site with preponderance of nodes. 
TYPES OF NECK DISSECTION 
In a classic radical neck dissection, the superficial and deep 
cervical fascia with its enclosed lymph nodes (levels I to V) is 
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removed  in continuity with the sternocleidomastoid muscle, the 
omohyoid muscle, the internal and external jugular veins, cranial 
nerve XI, and the submandibular gland. The radical neck dissection 
can be modified to spare certain structures with the intent of 
decreasing morbidity and improving functional outcome without 
compromising disease control. There are three main types of 
modified radical neck dissections 
Type I, CN XI is spared; 
Type II, CN XI and the internal jugular vein are spared; and 
Type III (functional), CN XI, the internal jugular vein, and 
the sternocleidomastoid muscle are spared.  
 Selective neck dissections are more limited and include the 
resection of lymph node levels that are at greatest risk for nodal 
metastatic spread. Examples include the lateral, posterolateral, and 
supraomohyoid, which include resections of lymph node levels II 
through IV, II through V, and I through III, respectively. The 
extended supraomohyoid neck dissection includes level IV nodes 
along with level I , II, III nodes. 
 A modified or selective neck dissection is recommended for 
the cN0 neck, for selected clinically positive necks (mobile, 1 to 3 
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cm lymph nodes), and for removing residual disease after RT when 
there has been excellent regression of N2 or N3 disease.
10 
 The 
more extensive the neck dissection, the higher the risk of 
complications. Both RT and neck dissection are approximately 90% 
efficient at eradicating subclinical regional disease. The salvage 
rate for patients developing clinically positive lymph nodes with 
the primary lesion controlled is 50% to 60%. Elective neck 
irradiation (ENI) and elective neck dissection are equally effective 
in the management of the N0 neck, with control rates exceeding 
90%. Treatment of the entire neck is advised for primary lesions 
with a high rate of subclinical disease, such as the base of tongue, 
soft palate, supraglottis, and hypopharynx.  In general, RT precedes 
surgery if the primary site is to be treated by RT or if the node was 
fixed. The operation precedes RT if the primary site is to be treated 
surgically. Modified neck dissection is sufficient treatment for the 
ipsilateral neck for patients with N1 or N2A disease without ECE. 
RT, often combined with concurrent chemotherapy, is added for 
those with more advanced neck disease. Complications after neck 
dissection include hematoma, seroma, lymphedema, wound 
infections and dehiscence, damage to the 7th, 10th, 11th, and 12th 
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cranial nerves, carotid exposure, and carotid rupture. Pain and 
dysfunction in the neck or shoulder may occur. 
RADIOTHERAPY 
The advantages of RT may include 
1) The risk of a major postoperative complication is avoided, 
2) No tissues are removed so that the probability of a functional 
or cosmetic defect may be reduced,  
3) Elective neck RT can be included with little morbidity, and 
4) The surgical salvage of RT failure is probably more likely 
than the salvage of a surgical failure. 
CONVENTIONAL FRACTIONATION 
Standard fractionation for radiation therapy is defined as the 
delivery of one treatment of 1.8 to 2.25 Gy/d upto a dose of 66 – 
70Gy over a period of 6 - 7 weeks. 
ALTERED FRACTIONATION 
Accelerated Radiotherapy: 
Decreases the overall treatment time so that the tumor cells 
regenerate less during the treatment and hence better loco regional 
control is achieved. 
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Pure accelerated radiotherapy 
There is a decrease in the overall treatment time but no 
change in the total dose or fraction size. 
Hybrid accelerated fractionation:There are three types.  
Type A:Drastic reduction in overall treatment time and a 
considerable decrease in the total dose. 
Type B: Treatment time is decreased, total dose remains the 
same with an added break in between treatment.  
Type C: Total dose is same; overall treatment time is reduced 
with an addition of a concomitant boost phase (Accelerated 
concomitant boost). 
Hyper Fractionated Radiotherapy 
In hyper fractionated radiotherapy, dose of radiation is 
increased, dose per fraction is significantly reduced, the numbers of 
fractions are increased and overall treatment time is significantly 
unchanged. 
Hypo fractionated radiotherapy 
  Here the dose per fraction is increased, the number of 
fractions is reduced, total dose is decreased, and the overall 
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treatment time is significantly reduced. This is mainly used for 
palliative radiotherapy. 
RATIONALE FOR ALTERED FRACTIONATION: 
The most fundamental principles of fractionated radiotherapy: 
 Repair,  
 Reassortment  
 Repopulation  
 Reoxygenation, 
Elkind et al. found that the survival of cells increased with 
increasing time between doses for up to a maximum of about 6 
hours. This finding is consistent with the clinical observation that 
separation of radiation treatments by 6 hours produces similar 
normal tissue injury as a 24-hour separation.
11 
 The shoulder of a 
survival curve is strongly influenced by sublethal damage repair : 
the broader the shoulder the more SDR and the smaller α/β ratio.  
Similar to repair, reassortment and repopulation are also 
dependent on the interval of time between radiation fractions. If 
cells are given short time intervals between doses, they can 
progress from a resistant portion of the cell cycle (e.g., S phase) to 
a sensitive portion of the cell cycle (e.g., G2 phase). This transit 
between resistant and sensitive phases of the cell cycle is termed 
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reassortment. If irradiated cells are provided even longer intervals 
of time between doses, the survival of the population of irradiated 
cells will increase. This increase in split-dose survival after longer 
periods of time is the result of cell division and has been termed 
repopulation. Reassortment and repopulation appear to have more 
protracted kinetics in normal tissues than rapidly proliferating 
tumor cells and thereby enhance the tumor response to fractionated 
radiotherapy compared to normal tissues. Similarly Reoxygenation 
also plays a vital role in tumour control. The cells in the center part 
of tumour is usually hypoxic due to lack of oxygen because of 
impermeability of blood vessels till the center of the tumour. Once 
the cells in the periphery which is oxic gets destroyed, the cells in 
the center receives blood from the blood vessels and becomes oxic 
which is susceptible to further radiation.   
Radiotherapy is incorporated in the various steps of 
management in the squamous cell carcinoma of head and neck. It 
can be given as 
DEFNITIVE RT 
Mainly for early stage disease as a single modality with good 
tumour control equivalent to that of surgery. It can be given as 
EBRT alone in the form of 2D conventional (whose usage has been 
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reduced now a days) , 3D Conformal radiotherapy, IMRT, IGRT. 
Conformal radiotherapy techniques increases the therapeutic ratio 
by increasing the tumour control and reducing the normal tissue 
toxicities. In other words they increase the tumour control 
propability and also decrease the normal tissue complication 
probability. They have mainly reduced the incidence of xerostomia, 
thereby increasing the quality of the patients till their survival.  
EBRT can be combined with brachytherapy for certain 
accessible sites thereby increasing the tumour dose without 
additional toxicities with the help of sharp dose fall off to the 
surrounding tissues.  
PRE OPERATIVE RT 
Most of the tumours in locally advanced stage such as stage 
III and stage IV are upfront inoperable. But the chance of cure is 
impossible without surgery. In those patients RT is given along 
with chemotherapy to reduce the bulk of the disease thereby  
helping the surgical oncologists to resect the tumour with adequate 
clearance. The usual dose given for this purpose is around 50 Gy 
and the patient is taken up for surgery after 4 weeks with proper 
assessment of the reduction of disease. 
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POSTOPERATIVE  
 Postoperative RT is indicated in patients with high risk 
features following surgery such as  
 Tumour stage T3 , T4 
 Nodal positivity 
 Margin positivity 
 Extracapsular extension 
 Lymphovascular invasion 
 Perineural invasion 
Margin positivity and the Extracapsular extension are the 
indications of chemoRT. 
PALLIATIVE RT 
 Palliative RT is usually considered in very advanced disease 
with poor performance status for whom cure is impossible due to 
extensive nature of the disease. It is usually given as 
hypofractionated radiotherapy in high doses to palliate symptoms 
like bleeding , pain. 
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CONCURRENT CHEMORT 
   Radiation can be combined along with chemotherapy to 
increase the tumour control thereby increasing disease free survival 
and overall survival. So these are mainly used in the management 
of locally advanced cancers to get better therapeutic effect. Altered 
fractionation schedules of RT  lead to a 7% to 10% improvement in 
locoregional control relative to once-daily treatment schemes. Even 
the most effective RT regimens result in local control rates of 50% 
to 70% and disease-free survivals (DFSs) of 30% to 40%. These 
results has stimulated the investigation of treatments combining RT 
and chemotherapy. Chemotherapy can be combined along with RT as  
 Induction or Neoadjuvant chemotherapy 
 Concurrent along with RT 
 Palliative chemotherapy. 
A meta-analysis of individual patient data from >17,346 
participants in 93 trials conducted from 1965 to 2000 (Meta-
Analysis of Chemotherapy on Head and Neck Cancer [MACH-NC]) 
demonstrated that the use of radiotherapy and concurrent 
chemotherapy (CRT) resulted in a 19% reduction in the risk of  
death and an overall 6.5% improvement in 5-year survival 
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compared to treatment with RT alone (p < .0001). This benefit was 
predominantly attributable to a 13.5% improvement in local 
regional control. The 2.9% reduction in the risk of distant  
metastases was not statistically significant. The MACH-NC also 
demonstated a 2% improvement in 5year survival with the use of 
induction chemotherapy followed by RT which is not significant.  
Concurrent chemoRT is the most commonly accepted and 
beneficial because some chemotherapeutic agents may both radio 
sensitize cells and provide additive cytotoxicity. The superiority 
has also been demonstated in other squamous cell carcinomas of 
other anatomic sites including oesophagus and cervix. Also a 
thorough understanding of toxicity is essential since the morbidity 
of loss of function due to surgery is better avoided with concurrent 
chemoRT. A recent analysis of phase III trials comparing RT with 
chemoRT suggests that concurrent chemotherapy provides the 
equivalent of a 10- 12 Gy dose escalation. Also chemotherapy 
addition shows better response when added to altered fractionation 
though there is mild increase in acute toxicity.  
Some drugs which are commonly used along with RT 
includes Platinum compounds, antimetabolites, taxanes, mitomycin, 
bleomycin, vinca alkaloids, etc. Among these CDDP has got a 
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proven role in the management of  head and neck scc at advanced 
stage.. Among the recent studies taxols also play a vital role along 
with RT. 
CISPLATIN 
Cisplatin and its analogs react preferentially at the N7 
position of guanine and adenine residues and forms a variety of 
monofunctional and bifunctional adducts. The monoadducts may 
form intrastrand or interstrand cross-links. The formation of 
adducts and cross-links has been associated with therapeutic 
efficacy.
12 
These adducts are responsible for the drug’s cytotoxicity 
because they impede certain cellular processes that require the 
separation of both DNA strands, such as replication and 
transcription.though the combination chemotherapy of CDDP and 5 
FU yield good results, the toxicities such as mocositis is still high 
in the combination arm than single agent chemotherapy arm.  
THREE WEEKLY CHEMO VS WEEKLY CHEMO 
Cisplatin is given as a single agent the dose as 100 milligrams 
per square metre of body surface area every three weekly. This high 
dose is associated with increased mucositis, increased vomiting and 
renal toxicity. This necessitates more intensive care and has 
attendant resource implications. This also results in treatment delay  
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or at least decrease in patient compliance. Therefore it is logical to 
split high dose three weekly cisplatin into weekly cisplatin schedule 
so that the toxicities are decreased and patient compliance is 
increased while maintaining dose intensity. Many trials have 
showed that weekly cisplatin is a safe alternative to three weekly 
cisplatin without compromising the efficacy. More over in weekly 
cisplatin arm we can monitor patients every week and dose 
adjustments can be made if necessary. Hence weekly cisplatin is a 
more acceptable regimen than three weekly cisplatin. Also the total 
dose of cisplatin 200mg is essential to achieve the therapeutic 
effect similar to that of 3 weekly regimen. 
PACLITAXEL 
 This is an antimicrotubule agent which acts by arresting the 
cells at G2M phase thereby increasing the cells exposed to 
radiation. This is first tried along with other drugs for induction 
chemotherapy and proved to be effective. Later due to its 
radosensitization effect, weekly paclitaxel trials have tried and 
proved to be effective along with RT. The addition of paclitaxel to 
carboplatin or cisplatin in weekly therapy with CRT has great 
appeal because of the synergy between these drugs and the 
significant radiation-sensitizing properties of the taxanes. 
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TARGETTED AGENTS 
Most of the head and neck cancers in Indian population have 
EGFR overexpression and the molecules targeting this have a great 
impact in the management of head and neck cancers. Of these 
tyrosine kinase inhibitors and monoclonal antibodies are upcoming. 
The drug approved by phase III STUDIES is Cetuximab. Other 
drugs commonly used in trials are Nimotuzumab, Geftinib, 
Erlotinib. These drugs have been proved effective and less toxic 
when compared to chemotherapy in HPV positive oropharyngeal 
cancers. 
CHEMOPREVENTION 
Chemoprevention is the administration of natural or synthetic 
agents to reduce the risk of getting SPTs. Patients with head and 
neck SCC have an increased risk of developing an upper 
aerodigestive tract SPT because of exposure to carcinogens and/or 
genetic predisposition.  The risk of developing an SPT is 
approximately 2.7% to 4% per year and may impact survival. High-
dose13-cis-retinoic acid (100 mg/m
2
 daily for 12 months) has been 
shown in a randomized, placebo-controlled trial to reduce the risk 
of SPTs in patients previously treated for stage I to IV, M0, cancers 
of head and neck. Retinoids and beta-carotene both may cause 
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regression of oral leukoplakia; the former appear more efficacious.  
Lesions commonly recur after cessation of drug therapy. There is 
no standard role for the use of HR-HPV vaccination in the 
prevention of head and neck cancer at this time, although the 
impact of current vaccination programs on the incidence of head 
and neck cancer requires  follow-up. 
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LITERATURE REVIEW 
Radiotherapy plays a major role in the management of 
unresectable locally advanced head and neck squamous cell 
carcinoma over decades. Delivery of radiotherapy using modern 
techniques has improved the local control along with adequate 
sparing of normal tissues so that the patients are very compliant 
with minimal toxicities. Apart from conventional fractionation, 
various altered fractionation modalities have been developed in 
order to achieve increased locoregional control without increasing 
the toxicities. Altered fractionation with or without concomitant 
chemotherapy result in improved outcomes in the form of tumour 
control and survival compared with conventionally fractionated 
definitive RT alone for stage III-stage IV HNSCC.
13 
Two important features that influence the effectiveness of 
radiation are 1) the dose given during each radiation treatment ie 
dose per fraction 2) total amount of time necessary to complete the 
treatment. 
Accelerated fractionation used in the management of head 
and neck cancer was thought to arise from various analyses as a 
function of dose administered and total treatment time given. When 
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the total dose is increased there is improved locoregionl control but 
due to prolonged duration of treatment, the equivalent loss of local 
control was  about 0.75 Gy per day.
   
Study by withers et al showed 
that accelerated repopulation occurs usually after 28 days of 
treatment for head and neck cancers. A dose increment of 0.6 gy 
per day is necessary to compensate for this repopulation. 
Accelerated fractionation is defined as decrease in overall treatment 
time or  an increase in the average dose per week above 10 gy given 
in conventional fractionation. 
Concomitant boost irradiation is a technique where  two 
radiation fractions are given from fourth week of radiation therapy 
in order to compensate  accelerated repopulation in head and neck 
cancers. The boost is given only to the primary tumour site and the 
involved nodes. The main advantage of Concomitant Boost 
Radiotherapy  is that 
There is  increase in locoregional control of the tumour  
with minimal enhancement in acute toxicities as compared to 
other accelerated fractionation regimens  
 It shortens the total treatment duration  from seven weeks 
to five weeks. 
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ALTERED FRACTIONATION TRIALS 
RTOG 90-03 TRIAL compared various altered fractionation 
schedules such as HYRERFRACTIONATION Vs CONCOMITANT 
BOOST RT Vs SPLIT COURSE RT to standard CONVENTIONAL 
RT in locally advanced squamous cell carcinoma of head and neck. 
In this study 4 arms were randomized including 1073 patients of  
Stage III-IV (oral cavity, oropharynx, or supraglottic larynx) or 
Stage II-IV (base of tongue, hypopharynx).  
Arm 1) Conventional or standard fractionation 70/35 @ 2 
Gy/fx vs.  
Arm 2) HF hyperfractionated RT  81.6/68 @ 1.2 Gy BID vs.   
Arm 3) AFX-S split course accelerated fractionation 67.2/42 
@ 1.6 Gy BID with 2 week break after 38.4 Gy vs.  
Arm 4) AFX-CB concomitant boost radiation 72 Gy given 
54/30 @ 1.8 Gy + 18/12 @ 1.5 Gy concurrent BID boost 
RESULTS:  2 year and 5 year locoregional control rates were 
found to be better in HYPER FRACTIONATED  and 
CONCOMITANT BOOST  arms than STANDARD 
FRACTIONATION. Though acute effects were found to be 
increased as expected , the late effects were found to be reduced. 
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There is no significant difference between progression free survival 
and overall survival
14
. 
M.D.ANDERSON TRIAL in 1985-1988 treated patients wth 
carcinoma oropharynx and nasopharynx with CONCOMITANT 
BOOST RT. The treatment schedule includes 6 weeks to a 
maximum dose of 69-72 Gy with the boost consisting of 10-12 
fractions. They found better primary tumor control (p=0.11) if  the 
boost is given during last the last 10-12 fractions versus the first 
10-12 fractions or twice a week throughout the treatment.
15 
A Prospective phase II study of concomitant boost 
radiotherapy given for stage II nasopharyngeal carcinoma found 
that C-Boost radiotherapy regimen provides a substantially higher 
biologically effective dose compared with conventional radiation 
treatment. Preliminary locoregional control and survival rates are 
increased  with no significant acute and/or late toxicities.
16 
Prospective studies show that biologic dose escalation with 
Modified  fractionation (hyperfractionation or accelerated 
fractionation with concomitant boost) improves locoregional 
control (LRC) compared with standard fractionation in patients 
with advanced head and neck cancer .  In a recent meta-analysis, 
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enhanced LRC with modified fractionation translated into a 3.4% 
improvement in overall survival (OS) at 5 years
18
 . 
GHOSHAL S conducted a phase III Randomized trial in a 
single institution in INDIA, in which Patients were randomised  so 
that 
Conventional radiotherapy was given with 2 Gy/fraction/day, 
to a dose of 66 Gy in 33 fractions over 6.5 weeks or 
Accelerated radiotherapy in the form of  CONCOMITANT 
BOOST  to a dose of 67.5 Gy/40 fractions over 5 weeks (phase 1: 
45 Gy/25 fractions/5 weeks to the wide portal and phase 2: 22.5 
Gy/15 fractions/3 weeks as a second daily fraction ie the 
boostafter a 6h gap) to the tumour and the involved nodes. 
The primary and secondary end points were disease-free 
survival and locoregional control respectively. Patients treated with 
concomitant boost had a better 2-year disease-free survival (71.7% 
vs 52.17%, P=0.0007) and locoregional control rates (73.6% vs 
54.5%, P=0.0006) than with conventional fractionation.
19 
A study by Shrivatsava compared  Concomitant boost 
radiotherapy vs conventional radiotherapy in advanced oral cavity 
and oropharynx cancers reported  in the Department of 
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Radiotherapy, KGMC, Lucknow between Jan 1999 and Feb 2000. 
In Concomitant boost arm, 30 patients out of 40 patients (75%) and 
in Conventional RT arm 24 patients (60%) had complete response 
(CR) and the rest of the patients had partial response except for one 
patient in Group II who had no response (NR). Acute reactions 
were slightly higher in Concomitant boost arm and were easily 
managed by IVF support. There is no difference in the late 
reactions between the two groups. The main advantage of 
CONCOMITANT BOOST TECHNIQUE is that there is very 
minimal enhancement in acute reactions that can be managed 
well as compared to other accelerated fractionation regimens and 
another advantage is that it shortens the total treatment duration 
from seven weeks to five weeks
20
. 
Phase III randomised trial was conducted by Anupam rishi 
and Sushmita Goshal to compare concomitant boost radiotherapy 
against concurrent chemoradiation in locally advanced 
oropharyngeal cancers in single institution from INDIA : 216 
patients with histologically proven Stage III–IVA oropharyngeal 
cancer were randomly assigned between June 2006 and December 
2010 to receive either chemoradiation (CRT) to a dose of 66 Gy in 
33 fractions over 6.5 weeks with concurrent cisplatin (100 mg/m2 on 
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days 1, 22 and 43) or accelerated radiotherapy with concomitant 
boost (CBRT) to a dose of 67.5 Gy in 40 fractions over 5 weeks. 
The  2 year disease-free survival rates were similar with 56% in the 
chemo radiotherapy group and 61% in CBRT group (p = 0.2; HR-
0.81, 95%CI-0.53–1.2). Subgroup analysis revealed that patients 
with nodal size >2 cm had significantly better DFS with CRT (p = 
0.05; HR-1.59, 95%CI-0.93–2.7). Acute toxicities were 
comparatively higher in chemo radiotherapy arm when compared to 
concomitant boost arm. But the patients had improved quality of 
life with concomitant boost arm
21
. 
CONCURRENNT CHEMOTHERAPY WITH RADIATION 
Locally advanced squamous cell carcinoma of head and neck 
cancers management usually incorporates chemotherapy along with 
radiation to improve the tumour control, disease free survival and 
overall survival. This is achieved by two mechanisms: 
Radiosensitisation and Spacial additivity.  Radiosensitisation 
increases the effect of radiation on tumour by increasing the cell 
kill without increasing the dose of radiation. This radiosensitisation 
is achieved with many chemotherapeutic agents either single or 
combination agents such as Cisplatin, 5FU, paclitaxel, docetaxel , 
capecitabine, gemcitabine, vinorelbine. Selection of the regimen is 
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therefore important in order to achieve improved tumour control 
without causing any  treatment related breaks due to increased 
toxicities thereby preventing the delay in treatment completion.  
The MACH-NC conducted meta-analysis of 63 randomized 
trials (10,741 patients) that were published between 1965 and 1993 
and revealed that adjuvant chemotherapy provided a 4% 
improvement (P < .0001) in 5-year overall survival. This benefit 
was limited to those who received concomitant chemotherapy (8%; 
P < .001) and was not observed in patients who received induction 
or maintenance chemotherapy. But this report was criticized for its 
heterogeneity and was recently updated to include 24 new trials, 
85% of which explore concomitant chemotherapy. The results were 
unchanged:  
1) There was an 8% improvement in overall survival with 
concurrent chemoradiotherapy;  
2) Maintenance and induction schedules did not provide a 
significant survival benefit;  
3) All tumor sites were  benefited;  
4) Platinum-containing regimens showed the greatest benefit (an 
11% 5-year overall survival advantage); and 
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5) There was no difference between poly- and 
monochemotherapy. 
A recent update of Meta- analysis of chemotherapy on head 
and neck cancer (MACH-NC) showed that by adding chemotherapy 
along with radiation results in 19 % reduction in risk of death and 
8% improvement in overall survival compared to radiation therapy 
alone. Majority of these benefits are derived from concurrent 
chemo radiation. The 2 % improvement in survival by induction 
chemotherapy is not statistically significant
22 , 23
.  
Budach and coworkers published a meta-analysis of modern 
chemotherapy regimens and curative intent RT doses (>60 Gy). The 
analysis included 32 trials (10,225 patients) published between 
1975 and 2003. Their report showed an overall survival benefit of 
12 months for chemotherapy concurrent with conventional or 
altered fractionation RT
24
. 
Even though concurrent chemo radiation increases the 
toxicities of radiation, it exerts a good loco regional and systemic 
control. Hence concurrent chemo radiation is standard of care 
in locally advanced squamous cell carcinomas of head and neck.  
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EQUIVALENCE OF CHEMOTHERAPY TO 
RADIOTHERAPY 
From RTOG 90-03, a 1% increase in BED is associated with 
a 1.1% increase in Locoregional control. The mean BED of 
standard fractioned radiotherapy was found to be  60.2 Gy10 and 66 
Gy10 for modified fractionation. The mean BED of standard frac-
tionated chemoradiotherapy was found to be 71 Gy10 (10.8 Gy10 
contributed by chemotherapy). The mean BED of modified 
fractionated chemoradiotherapy was found to be 76 Gy10 (10.4 
Gy10 contributed by chemotherapy)
25
. Chemotherapy increases 
BED by approximately 10 Gy10 in both standard and modified 
fractionated radiotherapy, equivalent to a dose escalation of 12 Gy 
in 2 Gy daily or 1.2 Gy twice daily. Such an escalation could not be 
safely achieved by increasing radiation dose alone. Thus, 
combined-modality therapy should be the preferred method to 
enhance LRC and OS in locally advanced head-and-neck cancer. 
Efforts should be made to investigate the mechanisms underlying 
the unique biologic benefit achieved with chemotherapy or targeted 
therapy in combination with RT. 
CHEMOTHERAPY ALONG WITH CONCOMITANT BOOST 
RTOG 99-14 enrolled locally advanced squamous cell 
carcinoma of head and neck and treated with chemoradiation in the 
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form of  concomitant boost radiation along with INJ Cisplatin to 
evaluate the feasibility of combining concomitant boost accelerated 
radiation regimen (AFX-C) with cisplatin and to assess its toxicity 
and the relapse pattern and survival in patients with advanced head 
and neck carcinoma. 
76  patients were treated with Radiation which  consisted of 
72 Gy in 42 fractions over 6 weeks (daily for 3.5 weeks, then twice 
a day for 2.5 weeks) along with Cisplatin dose  100 mg/m
2
 on days 
1 and 22.  Complete response to therapy was found  in 63 patients 
(83%). The estimated 2-year locoregional relapse and distant 
metastasis rates were 34.7% and 16.1%, respectively. The estimated 
2-year overall survival and disease-free survival rates were 71.6% 
and 53.5%, respectively. LR failure noted was 33% (2 yr) and 36% 
(4 yr).  OS was found to be  70% (2 yr) and 54% (4 yr). Grade 3 – 4 
late toxicity found was  42%. Though the acute toxicities were 
increased, patients were very compliant with the treatment
26
. 
Another study by Teh BS using concurrent chemotherapy of 
cisplatin 100mg/m
2
 in the frst and last week of treatment  along 
with Concomitant boost radiotherapy upto a dose of 70 Gy in 6 
weeks  showed 65% of complete response and 35% of partial  
response
27
. Though there were increased acute confluent mucositis 
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in 50% of patients, there were no enhanced  treatment related late 
toxicity. They concluded that this combined chemoradiotherapy is 
safe and efficacious. 
Another study conducted in our institute during the year 2006 
using concomitant boost radiotherapy of 72Gy in 6 weeks along 
with Inj Cisplatin 100mg/m
2
 on day 1 and 22 showed complete 
response rate of 79.1% with a partial response of 16.7%and 
progressive disease was noted in 4.2%. The study concluded that 
this study is very compliant to the patient with enhanced 
locoregional control and manageable acute toxicities. 
WEEKLY CISPLATIN 
HEATHER E NEWLIN did a trial with  Concomitant weekly 
cisplatin and altered fractionation radiotherapy in locally advanced 
head and neck cancer. The routine chemotherapy schedule includes 
3 weekly cisplatin 100 mg/m2. Both altered fractionation and 
cisplatin causes increased acute toxicity. But there is a debate 
whether weekly cisplatin can be used along with altered 
fractionation. The authors' purpose  of this study was to evaluate 
the efficacy and toxicity after weekly cisplatin (30 mg/m
2
/wk) 
given along with altered fractionation RT. 
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One hundred twenty-one patients with American Joint 
Committee on Cancer stages II (3%), III (13%), or IV (84%) 
squamous cell carcinomas of the oropharynx (70%), hypopharynx 
(20%), or larynx (10%) were treated between 2000 and 2006 at the 
University of Florida with hyperfractionated RT (55 patients) or 
concomitant boost RT (66 patients) and concomitant cisplatin (30 
mg/m
2
/wk). 
The 5-year outcomes were: local control of 83%; locoregional 
control of 79%; distant metastasis-free survival of 88%; cause-
specific survival of 76%; and overall survival of 59%. They 
concluded that Concomitant weekly cisplatin with altered 
fractionation RT is a safe and effective treatment regimen
28
. 
PACLITAXEL TRIALS 
Initially paclitaxel was given for head and neck cancers in a 
recurrent and metastatic settings and proved to be beneficial. Later  
paclitaxel was tried in concurrent setting along with radiation either 
as a single chemo or in combination. The main dose limiting 
toxicity was febrile neutropenia. So various doses were tried in 
concurrent settings. Hoffman et al did an interesting study to 
define the maximum tolerated dose of paclitaxel given as weekly 
intravenous infusion concomitant with radiation by describing the 
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dose limiting toxicity in Head and neck cancer patients and he 
concluded that 30 mg/m2 is the maximum tolerated dose of weekly 
paclitaxel concomitant with radiation with mucositis as the dose 
limiting toxicity and only mild haematological toxicities
30
. By 
causing mitotic arrest and accumulating cells in radiosensitive 
phases like G2 and M phase ( redistribution of cells), by 
eliminating hypoxic cells in the tumour and by causing 
programmed cell death, Paclitaxel act as 10 times more radio 
sensitizer than cisplatin. 
Garden et al conducted a study in concurrent chemo 
radiotherapy with 3 arms – one arm with weekly cisplatin 20mg/m2 
and weekly paclitaxel 30mg/m
2
 . this showed equal response rate 
with that of cisplatin and 5FU arm
29
. The toxicities were also 
comparable. But large randomised trial was not continued with this 
study. 
RATIONALE FOR THIS STUDY 
This study is mainly based on combining chemotherapy with 
Altered  Fractionation regimen to get enhanced locoregional control 
in advanced setting. 
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Concomitant Boost technique is chosen thereby to increase 
the response rate without excessive toxicities and also the treatment 
time is reduced from 7 weeks  to 5 weeks. Cisplatin and paclitaxel 
was chosen as weekly regimen inorder to potentiate the effects of 
radiation. Cisplatin is the drug proved to be effective in 
metaanalyses with dose of 200mg in 5 weeks is comparable to 3 
weekly cisplatin. Paclitaxel by arresting the cells at G2M phase 
increases the sensitising effects of radiation. The study is planned 
to increase the total dose within the short period of time with 
enhanced effects of low dose chemotherapy without increasing the 
morbidity due to toxicities. 
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AIMS AND OBJECTIVES 
The main aim of  this study is to evaluate the use of  Altered 
fractionation in the form of Concomitant boost along with low dose 
chemotherapy in the form of weekly CDDP and Paclitaxel.  
PRIMARY OBJECTIVE (S)  
To assess the  immediate locoregional response rates of 
locally advanced  squamous cell carcinomas of the head and neck 
treated with concomitant boost radiotherapy and chemotherapy 
using low dose weekly cisplatin and paclitaxel. 
SECONDARY OBJECTIVE(S)  
To Evaluate the acute toxicity to the treatment. 
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MATERIALS AND METHODS 
STUDY DESIGN 
This was a Single arm prospective study with a Phase II 
design. 
STUDY DURATION  
January 2015 - August, 2015 
STUDY CENTRE 
Department of Radiotherapy, Barnard Institute of Radiology 
& Oncology, Madras Medical college, Chennai. 
SAMPLE SIZE  
30 consecutive patients with histopathologically proven 
squamous cell carcinoma of head and neck who were fit for 
inclusion criteria were recruited in the study from the outpatient 
department.  
The intent of treatment was to be radical, aiming for cure, 
considering their disease stage, co- morbidities and performance status 
ETHICAL COMMITTEE APPROVAL  
Approval from the institute ethical committee was obtained 
on 20.01.2015. 
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INFORMED PATIENT CONSENT  
All patients enrolled in the study were informed about the 
merits and demerits of participating in this study and signed an 
informed consent form in their regional language,which is Tamil.  
INCLUSION CRITERIA 
 Biopsy proven newly diagnosed squamous cell carcinoma of 
the head & neck.  
 Primary tumor sites: oral cavity, oropharynx, hypopharynx, 
larynx.  
 Age 20- 60 years  
 Stage III or IV locally advanced squamous cell carcinoma  
 Previously not exposed to any chemo or radiotherapy  
 ECOG 1-2  
 No major life threatening comorbidities 
EXCLUSION CRITERIA 
 Non Squamous Histopathology  
 Tumors of nasal cavity, paranasal sinuses and nasopharynx.  
 Bone and cartilage involvement. 
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 Inadequate hepatic and renal functions, bone marrow reserve.  
 Patient not consenting to chemotherapy at any point in the 
treatment.  
 Previously received  treatment for any other malignancy.  
 Metastatic or recurrent disease. 
 Patients with uncontrolled co morbid conditions like diabetes, 
hypertension. 
 Pregnant females. 
PRE TREATMENT WORK UP 
1) Detailed history including presenting symptoms, past history, 
personal and family history. 
2) Complete physical examination by inspection, palpation.  
3) Upper aerodigestive tract evaluation by direct and indirect 
laryngoscopy, anterior and posterior rhinoscopy and 
endoscopy if indicated to know the extent of disease and rule 
out a second primary. 
4) Biopsy from the primary tumor and/or fine needle aspiration 
cytology from the metastatic lymph node. 
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5) Blood grouping and typing. 
6) Complete blood count. 
7) Renal function test. 
8) Liver function test. 
9) CT scan of the base of the skull to root of the neck  plain and 
contrast, before initiating treatment and also after 6 weeks of  
treatment for response assessment. 
10) Chest X ray postero-anterior view.  
11) Viral markers. 
12) Cardiac evaluation and fitness.  
13) Naso-gastric tube insertion if indicated  
14) Dental prohylaxis including scaling, dental filling and 
extraction if required.  
15) Tumour stage, performance status , weight , body surface 
area, creatinine clearance were recorded. Staging was done 
based on American Joint Committee staging manual 7
th
 
edition (for head and neck cancers). 
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16) Weekly CBC, RFT, LFT before each cycle of chemotherapy.  
PATIENT PREPARATION DURING TREATMENT 
All patients included in the study were told about the nature 
of the disease, stage and prognosis, treatment options , benefits of 
this study and informed consent for the same. 
All patients enrolled in this study were distributed pamphlets 
describing in brief the do’s and don’ts while on treatment and later.  
NO TOBACCO AND ALCOHOL 
The harmful effects of tobacco, both in smoking and 
smokeless  form, and alcohol were explained to the patient and 
draw backs of its addictions  to treatment was explained. These 
addictions has poor outcome after treatment and has increased risk 
of second malignancy due to field cancerization effect. 
DENTAL PROPHYLAXIS 
All the patients with oral cavity and oropharynx malignancies 
were advised dental evaluation and further management such as 
scaling, filling and extraction of the tooth if required in situations 
such as sharp teeth causing continuous irritation, caries tooth. They 
were started on antibiotics and analgesics following tooth 
extraction. A gap of 2 weeks after last  teeth extraction was given 
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prior to the treatment of radiotherapy for proper wound healing of 
the gums. They were advised to use soft brush and fluoride 
containing tooth pastes twice daily. Artificial dentures are placed 
after completion of treatment after resolvement of toxic reactions, 
only then proper measurements can be got. Edentulous patients 
were evaluated for their oral hygiene any retained root tips. Patients 
were advised not to wear dentures until the mucosa is healed from 
the effects of radiotherapy. Regular mouth goggling was adviced  
Thus in this study patients were suggested following oral 
measures to improve their oral hygiene during radiation. 
 Patients oral health were monitored daily twice during 
treatment. 
 All patients were advised to gargle 20 to 25 mL of 
indigenously prepared mouthwash by dissolving three 
teaspoons of soda bicarbonate and three teaspoons of table 
salt (sodium chloride) in 200ml of distilled water, for every 4 
to 6 hours.  
 Morphine sulfate mouthwash was used as an alternative to 
produce pain relief .Alcohol free commercial mouth wash was 
also used.  
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 Patients who developed mucositis were managed in addition 
with antibiotics and low dose corticosteroids. Oral candidiasis 
was treated with tablet Fluconazole 150 mg per oral for 7 
days. Oral lozenges was also given. 
 Oral physiotherapy - in the form of mouth stretching and 
mouth opening exercise also advised to patients to avoid 
trismus. 
NUTRITIONAL CARE 
All the patients  enrolled in the study were assessed for their 
nutritional status by their intake of the quality and the quantity of the food 
taken by them. They were advised to take high protein diet prepared in 
their homes. A protein supplement and vitamins were given since the 
beginning of the treatment. They were given eggs. They were advised to 
take a simple preparation containing banana , egg , milk and sugar. 
Most of the patients in this study were presented with dysphagia 
and odynophagia. According to the grade of dysphagia, they were advised 
oral feeding or naso gastric tube feeding. 3 of my patients had feeding 
jejunostomy. They were given total parenteral nutrition also.  
Most of the patients developed mucositis since third week  of 
the treatment they find difficulty in maintaining the nutritional 
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status. They were threated with low dose steroids and supportive 
measures. Liquid preparations such as fresh fruits and vegetable 
juices were advised that time. Also eating of spicy foods was not 
encouraged. Periodical monitoring of weight of the patients were 
done and advises given to them accordingly. 
Before initiation of treatment, it was made sure that all 
patients had normal blood, renal and liver function tests and 
everyone had given written consent for the treatment.  
TREATMENT PROTOCOL 
30 locally advanced squamous cell carcinoma of head and 
neck cancer patients were selected consecutively from the 
outpatient department, who then underwent the pre treatment work 
up as mentioned before.  
RADIATION THERAPY  
All 30 patients were treated  with a Theratron Phoenix Tele 
Cobalt-60 machine.  
PATIENT POSITION  
Patients were made to lie in the supine position with neck 
slightly extended.  
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PATIENT IMMOBILIZATION  
Strict immobilization was practiced while irradiating the 
patient.  
RADIATION PORTALS 
Patients were treated with opposing lateral radiation portals.  
VERIFICATION  
X-ray simulation was done after making  the patient lie in the 
same treatment position to verify the treatment field.  
RADIATION DOSE  
Eligible patients are treated with Radiotherapy using 
concomitant boost technique consisting of 5gy/1.8gyper# /25#  -  5 
weeks,to a field 1 composing of tumour plus 2 cm clearance and 
invoved nodes along with possible microscopic nodes. 
22.5gy/ 1.5gy per# /15# to a field 2   given as a boost only to 
small field including primary and involved node at an interval of 6 
hrs during last 3 weeks of treatment to a total dose of 67.5 Gy 
within 5 weeks of treatment. 
DOSE CONSTRAINTS 
Following were considered:  
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 Tolerance dose of spinal cord- 45 Gy in conventional 
fractionation for 5 to 10 cm.  
 Parotid - up to 26 Gy after which permanent xerostomia is 
expected to occur.  
CHEMOTHERAPY SCHEDULE  
Inj Paclitaxel 20mg/m
2 
 - day 1, 8 15, 22, 29 and 
Inj CDDP 30mg/m
2
 – day 1,8,15,22,29  given 1 hr prior to 
radiotherapy. 
Renal and hematologic parameters were assessed prior to 
each cycle of chemotherapy. 
PREMEDICATION  
Premedication was given 12 hours before and 30 minutes 
prior to chemotherapy which included the following:  
 Inj. Ondansetron 8 mg IV.  
 Inj. Dexamethasone 8mg IV.  
 Inj. Ranitidine 50 mg IV.  
 Inj. Chlorpheniramine 4mg IV. 
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All the patients were hydrated with 1 pint of normal saline 
efore the start of chemotherapy. First Inj Paxlitaxel was given along 
with 500ml of normal saline over 2 hrs followed by 1 pint of 
normal saline. Then inj CDDP was given along with 500ml normal 
saline over 2 hours. Inj Mannitol was then given followed by one 
more pint of normal saline. Inj ondansetron and inj rantac were 
given for 2 days bd after chemotherapy.  Inj pacltitaxel should be 
monitored carefully for acute hypersensitivity reactions and should 
be stopped immediately. 
If reanal function tests found altered adequate hydration was 
given to the patient and the nephrologist opinion obtained for the 
the modification of dosage of drugs during subsequent cycles. But 
almost all the patients tolerated well the complete treatment.  
ASSESSMENT DURING CHEMORADIATION  
TOXICITY ASSESSMENT  
All the patients were examined daily before radiotherapy for 
reactions like Mucositis. 
LARYNGITIS 
Dysphagia and Skin reactions. Also the toxicities related to 
chemotherapy such as nausea and vomiting were also assessed.  
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Complete blood count and biochemistry will be monitored on 
a weekly basis. Chemoradiotherapy induced toxicity will be graded 
using Common Toxicity Criteria version 4.03  and RTOG acute 
radiation morbidity scoring criteria. In the case of WBC less 
than 1000/µl or platelets less than 50,000/µl for a period longer 
than 5 days, or in the case of any severe grade 3 or 4, radiation 
therapy will be interrupted until recovery and drug doses will be 
reduced by 10% in the next cycle. Mucositis grade III would need 
suspension of radiation. 
Mucositis was best treated with low dose steroids and 
antibiotics. Superadded infections such as candidiasis should also 
be noted and were treated  with antifungals clotrimazole lozenges 
and flucanozole tablets. Saliva supplements and regular mouthwash 
advised for dryness of mouth. Skin reactions were treated with 
cansafe cream after completion of the treatment.  
Blood investigations were repeated every week before 
chemotherapy and hemoglobin < 10g% was corrected by blood 
transfusion. Colony stimulating factor G_CSF  was given  when the 
Absolute Neutrophil Count fell below 1000 cells/cubic millimeter 
in a dose of 300mg. Symptomatic thrombocytopenia was corrected 
by platelet transfusion. 
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RESPONSE EVALUATION  
All patients were reassessed by clinical examination , ENT 
examination with laryngoscopy and with a contrast enhanced CT 
Neck, 6 weeks after completion of concurrent chemo radiation. 
Response to treatment was described which depends on the 
Response Evaluation Criteria in Solid Tumors (RECIST 1.1 
version) Criteria. 
 Complete Response: Disappearance of all target lesions; 
malignant nodes <10 mm.  
 Partial Response: A minimum of 30% reduction in the sum of 
the longest diameter of target lesions, taking the baseline 
study as reference; confirmed at 4 weeks.  
 Stable Disease: Neither partial response nor progressive 
disease criteria are met, in a minimum time set by the 
protocol.  
 Progressive Disease: At least 20% increase in the sum of the 
diameter, with a minimum absolute increase of 5 mm, taking 
as reference the smallest sum in the study or appearance of 
new lesions.  
 
 58 
FOLLOW UP 
 Patients after completion of concurrent chemoradiation were 
discharged from the hospital. Response evaluation was done 
based on RECIST criteria after 6 weeks.  
 Chest imaging, dental evaluations were done when indicated 
clinically. Continued smoking cessation, counseling to the 
patient and attender, rehabilitation, speech and swallowing 
therapy. 
 Patients with complete response were kept for follow up. 
Patients with partial response was assessed for salvage 
surgery and if not feasible was started on palliative 
chemotherapy.  
STATISTICAL ANALYSIS  
The patient factors, tumor factors, response to treatment, and 
toxicities were thoroughly analyzed. The results are expressed in 
percentage. Since this  study is single armed one and also the 
sample size was only 30, the levels of significance cannot be 
commented on. 
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TREATMENT PROTOCOL 
Patient Selection Based on inclusion criteria 
 
Pretreatment evaluation including blood investigations, Imaging 
and Dental prophylaxis 
 
Treatment administration- concomitant boost irradiation with 
weekly low dose cispatin and paclitaxel 
 
Response assessment every week and Regular monitoring of 
toxicities 
 
Treatment completion 
 
 Review after 6 weeks for response assessment  
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RESULTS AND ANALYSIS  
30 patients were enrolled in the study. All of them completed 
their treatment protocol completely and were available for analysis 
of results. 
PATIENT CHARACTERISTICS: 
AGE DISTRIBUTION 
30 patients enrolled in the study were from age 36yrs to 60yrs  
with good performance status. Majority of them were in 5
th
 decade 
followed by 4
th
 decade which is usually common in HNSCC 
patients. [ figure no:1] 
Table No:  1   Age Distribution Of Study Population 
Age group Number Percentage 
31 – 40 yrs  4 13% 
41 – 50 yrs 10 33% 
51 – 60 yrs 16 54% 
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GENDER 
There was a male preponderance in this study since males are 
highly exposed to common risk factors such as tobacco, alcohol etc 
and the incidence is also high in males. I recruited only 3 female 
patients since I selected patients with good performance status and 
body surface areato tolerate this intense regimen within 5 weeks. 
[figure no  : 2] 
Table No : 2  Gender Distribution Of Study Population 
Sex Number Percentage 
Male 27 90% 
Female 3 10% 
PERFORMANCE STATUS 
All the patients enrolled in this study were in a good 
performance status with  ECOG (Eastern Cooperative Oncology 
Group) grade 0 or 1. [figure no : 3 ] 
Table No : 3   ECOG Performance Status 
ECOG No of patients Percentage 
ECOG 0 17 57% 
ECOG 1 13 43% 
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RISK FACTORS  
Majority of the patients were exposed to risk factors such as 
tobacco both smoking and smokeless , alcohol. One female patient with 
chronic irritating ulcer due to sharp tooth had give rise to carcinoma. 
Table No:  4     Risk Factors Exposure     
Habits No of patients Percentage 
Tobacco(smoking) 17 57% 
Tobacco (smokeless) 9 30% 
Alcohol 20 66% 
None 4 13% 
SYMPTOMS AND SIGNS 
The most common presenting symptom among the study 
population was dysphagia followed by odynophagia  since most  of 
them are hypopharyngeal and oropharyngeal malignancies. 
[FIGURE NO :4]Table No:   5     Symptoms And Signs 
Presenting symptoms/signs Number Percentage 
Dysphagia 19 63% 
Odynophagia 16 53% 
Ulcer or growth 9 30% 
Neck swelling 8 26% 
Voice change  11 37% 
Pain 11 37% 
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PRIMARY SITE 
In this study Oropharynx were 9 patients, followed by 
Hypopharynx 8 patients then Oral cavity were 5 patients and larynx 8 
patients.(figure no:) . the subsites requiring unilateral fields were not 
added to this study because of intense toxicity expected due to increased 
radiationdose of 3.3gy/day along with chemotherapy.[ figure no: 5  ] 
Table No: 6   Primary Site 
Primary site Number Percentage 
Orophaynx 9 30% 
Hypopharynx 8 27% 
Oral cavity 5 16% 
Larynx 8 27% 
SUBSITE ANALYSIS 
In the subsite analysis, supraglottis and hypopharynx 
constitute the maximum number of cases. [figure no: 6  ]  
Table no:7  subsite analysis 
Subsite Number Percentage 
Supraglottis 8 26.66% 
Tonsil 6 20% 
Post 1/3 tongue 3 10% 
Pyriform fossa 8 26.66% 
Ant 2/3 tongue 4 13.33% 
Hard palate 1 3.33% 
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TUMOR STAGE 
This study included only squamous cell carcinoma of  head 
and neck in a locally advanced stage with T stages -  T2 (with node 
positive), T3, T4a . [figure no:  7 ] 
Table no: 8   Tumor stage  
T stage Number Percentage 
T1 0 0 
T2 4 13.33% 
T3 17 56.67% 
T4 9 30% 
NODAL STAGE 
Most of them had N 2 nodal disease . N 3 is not included for 
study purpose. [figure no: 8  ] 
Table no:  9    Nodal stage 
Nodal stage Number Percentage 
N0 4 13.33% 
N1 10 33.33% 
N2 16 53.34% 
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STAGE GROUPING OF THE STUDY SAMPLE 
The staging grouping was done according to AJCC 7
th
 
edition.  
Most of our patients present  only in locally advanced stage. 
[figure no: 9 ] 
Table no: 10   Stage Grouping 
Stage grouping Number Percentage 
STAGE III 14 46.67% 
STAGE IV A 16 53.33% 
HISTOLOGICAL DIFFERENTIATION 
Most of the patients in this study belonged to moderately 
differentiated histology. [ figure no: 10  ] 
 Table No:  11  Histological Differentiation 
Histological differentiation Number Percentage 
Well differentiated 9 30% 
Moderately differentiated 13 43.33% 
Poorly differentiated 8 26.67% 
 
 
 66 
TREATMENT RESULTS 
All 30 patients  have completed the treatment protocol and 
were assessed at the end of 4-6 weeks after chemoRT.  The 
evaluation was done clinically, which included ENT (Ear, Nose, 
Throat) examination with indirect laryngoscopy and direct 
laryngoscopy, and CT imaging (plain and contrast). The RECIST 
1.1 criteria were used to classify the response type into a complete 
response, partial response, static or progressive disease . 
RESPONSE RESULTS 
In this study 73% of the patients had complete response and 
27% had partial response. There was no static response or 
progression in the study. [figure no: 11  ] 
Table no: 12   Response Results 
Response Number Percentage 
Complete response 25 83.33% 
Partial presponse 5 16.67% 
Static response 0 0 
Progression 0 0 
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SUBSET ANALYSIS  
All the patient characteristics were analyzed  for response at 
the end of the treatment. The results are stated in percentage. Due 
to the single arm prospective analysis and small sample size of 30 
patients, the study tests of significance cannot be relied on.  
SITE VS RESPONSE 
In this study Oropharynx , Hypophaynx, supraglottis had 
equal number  of complete responses followed by oral cavity. 
[figure no: 12    ] 
Table no:13, Site Vs Response 
Site Complete Response Partial response 
Oralcavity 3(60%) 2(40%) 
Oropharynx 8(88.89%) 1(11.11%) 
Hypopharynx 7(87.50%) 1(12.50%) 
Larynx 8(88.89%) 1(11.11%) 
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SUBSITE VS RESPONSE 
Among the subsites involved, tonsil show complete response 
in all patients. Only ant 2/3 patients have equal number of partial 
and complete response. [figure no:   ]. Subsites with well 
differentiated histology shows poor response when compared to 
others. [ figure : 13] 
Table no: 14    Subsite vs Response 
Subsite Complete response Partial response 
Supraglottis 7(87.5%) 1(12.5%) 
Tonsil 6(100%) 0 
Post 1/3 tongue 2(66.67%) 1(33.33%) 
Pyriform fossa 7(87.5%) 1(12.5%) 
Ant 2/3 tongue 2(50%) 2(50%) 
Hard palate 1(100%) 0 
 
TUMOR STAGE VS RESPONSE 
3 patients of T4 stage and 2 patients of T3 stage showed 
partial response. All patients of T2 stage showed complete 
response. This denotes the bulk  of the tumour and the advanced 
nature of the disease. [ figure no : 14   ] 
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Table no: 15    Tumor Stage Vs Response 
Tumor stage Complete Response Partial response 
T1 0 0 
T2 4(100%) 0 
T3 15(88.24%) 4(11.76%) 
T4 6(66.67%) 3(33.33%) 
NODAL STAGE VS RESPONSE 
5 patients of N2 disease showed partial response because of 
increased number of nodes and multiple matted nature of nodes with 
central hypoxia due to increased size of the node. [ figure no:  15 ] 
Table no:  16     Nodal Stage Vs Response  
Nodal stage Complete Response Partial response 
NO 4(100%) 0 
N1 10(100%) 0 
N2 11(68.75%) 5(31.25%) 
 
HISTOLOGICAL DIFFERENTIATION VS RESPONSE 
As already mentioned maximum numbers of the patients in 
our study were moderately differentiated  in which 11 patients had 
complete response and 2 had partial response. All poorly 
differentiated cancer had complete response. Out of  9 well 
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differentiated tumors only 6  had complete, this is lower when 
compared to the other two differentiations. [figure no:   16  ]  
Table no:  17     Histological differentiation Vs response.  
Histologic differentiation Complete response Partial response 
Well differentiated 6(66.67%) 3(33.33%) 
Moderately differentiated 11(84.62%) 2(15.38%) 
Poorly differentiated 8(100%) 0 
STAGE GROUPING VS RESPONSE 
Among the 14 patients in stage III, 13 patients showed complete 
response and 1 patient showed partial response. Stage IV patients had 
reduced complete response when compared to sage III. [figure no :  17  ] 
Table no :  18     Stage Grouping vs Response 
Stage 
Grouping 
Complete Response 
Partial 
Response 
STAGE III 13(92.86%) 1(7.14%) 
STAGE IV 12(75%) 4(25%) 
PERFORMANCE STATUS VS RESPONSE 
The ECOG performance status among the study patients did 
not show much difference in the response rates, as the study 
patients are in the ECOG 0 OR 1. 
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Table no: 19     ECOG Vs Response 
ECOG Complete response Partial response 
0 16(94.12%) 1(5.88%) 
1 9(69.23%) 3(30.77%) 
 
OTHER FACTORS AFFECTING RESPONSE 
AGE 
In this study the age were not randomized  so its very 
difficult to interpret the results according to age group. Younger 
age because of their performance status had good outcome than old 
people with poor performance status. Also young age were well 
compliant to the treatment because of good performance status.  
GENDER VS RESPONSE 
As the male population dominated the study 85% of the males  
had complete response in contrast to 66% of the females. As the 
male and female ratio was not equivalent it cannot be considered as 
significant. 
TREATMENT BREAK VS RESPONSE 
Treatment delay due to toxicities which caused prolongation 
of overall treatment time was analyzed for response. There was 
treatment delay in 30% of the patients compared to 70% who 
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proceeded without delay in overall treatment time. Among the 30% 
of the patients, most of the patients had 1-3 days treatment break 
had 83% complete response whereas only 62.5% had complete in 
case of treatment break for 4 days or more. 
Though there was treatment break all patient  
completedchemoradiation. 
Table no: 20, Treatment break Vs Response 
Treatment break Number Complete response Partial response 
1-3 DAYS 5 3(60%) 2(40%) 
> 4DAYS 4 1(25%) 3(75%) 
 
 
TREATMENT RELATED ACUTE TOXICITIES 
ACUTE LOCAL TOXICITY 
Acute local toxicity is done by RTOG Acute morbidity 
scoring criteria.(Table 20, figure no: 18) 
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SKIN REACTION 
In this study 21 patients had Grade 1 skin reactions in the 
form of dry desquamation, decreased sweating. Another 7 patients 
had patchy moist desquamation whereas only 2 patients  had grade 
3 confluent moist desquamation only during the last week of the 
treatment. All patients wee treated with aloe vera cream and 
cansafe at the end of the treatment. 
MUCOSITIS 
Among the study population ,  6  patients had  grade 3 
mucositis  and 1 patient had grade 4 mucositis for whom RT was 
suspended till it heals. Pt was on regular mouth wash and 
antibiotics and analgesics.  13 patients had grade 2 mucositis and  
10 patients had grade 1 mucositis . These  were best managed with 
antibiotics, analgesics such as mucopain ointment.  
XEROSTOMIA 
Some patients developed altered  sensations of taste , hard 
sticky saliva during the treatment. Only 5 patients developed grade 
2 reactions, 17 patients developed grade 1 reactions and rest of 
them didn’t have much effects. 
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PHARYNGITIS 
Since many patients  presented with dysphagia , many of 
them advised NG tube  feeding from the beginning itself. During 
the couse of the treatment 18 patients had grade 2 phayngitis 
followed by 7 and 5 patients having grade 3 and grade 1 pharyngitis 
respectively. Even then the nutritional status was maintained due to 
proper advices.  
Table no:   21    Acute Toxicity 
Acute 
toxicity 
Grade           
0 
Grade 1 Grade 2 Grade 3 
Grade 
4 
Grade 
5 
Skin 
reactions 
0 21 (70%) 7 
(23.33%) 
2 
(6.67%) 
0 0 
Mucositis 0 10 
(33.33%) 
13 
(43.34%) 
6 (20%) 1 
(3.33%) 
0 
Salivary 
glands 
8 
(26.67%) 
17 
(56.67%) 
5 
(16.67%) 
0 0 0 
Pharyngitis 0 5 
(16.67%) 
18 (60%) 7 
(23.33%) 
0 0 
Laryngitis 0 6 (20%) 16 
(53.33%) 
8 
(26.67%) 
0 0 
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LARYNGITIS 
Some of the patients developed cough and symtoms of 
dyspnoea. Some petients with advanced laryngeal cancers had 
tracheostomy tube at the time of presentation in our department. 
Metal tracheostomy tube has been replaced with portex 
tracheostomy tube before starting radiotherapy. Grade 1, 2, 3, 
laryngitis were found in  6 , 16 , and 8 patients  respectively.  
SYSTEMIC TOXICITY 
The treatment related systemic toxicity was assessed with 
CTCAE V 4.03  and presented. [Figure no: 19   ]. Only minor 
systemic toxicities occurred during the treatment.  
Table no: 22   Systemic toxicity                                    
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
Nausea 20(%) 4 0 0 
Vomiting 10 5 0 0 
There  are  no diarrhea or cardiac toxicity during the 
treatment. 
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HAEMATOLOGICAL TOXICITIES 
ANAEMIA 
15 patients had adequate Hb levels during the treatment. 12 
patients had Hb dropped between 11 and 9.5 gms and were given 
iron tablets. Only 3 patients had Hb less than 9 gms in the third and 
fourth week of treatment and they were given packed cell 
transfusions. 
LEUCOPENIA AND NEUTROPENIA 
Leucpenia and neutropenia were found only in 7 patients 
during the course of the treatment. They were given Inj G_CSF 
300mg subcutaneously daily for 3 days along with antibiotics and 
home made foods. For this reason, chemotherapy schedule was 
little altered ie on the 4
th
 day of the week. No schedule has been 
missed by any of the patients. [figure no: 20] 
THROMBOCYTOPENIA 
There were no thrombocytopenia noted during the treatment 
among the study population.  
RENAL TOXICITY 
The patients had normal renal function tests through out the 
treatment. 
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Table no: 23     Haematological toxicity  
Haem toxicity Grade 0 Grade 1 
Grade 
2 
Grade 
3 
Grade 
4 
Anaemia 15(50%) 12(40%) 3(10%) 0 0 
Leucopenia 23(76.67%) 4(13.33%) 3(10%) 0 0 
Thrombocytopenia 0 0 0 0 0 
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 DISCUSSION 
Most of the patients in India presented with advanced stage to 
the hospitals due to their poor socioeconomic status, illiteracy , fear 
of neglect by the family and society. Now a days Head and Neck 
squamous cell carcinomas are becoming more prevalent in younger 
age group commonly below 40 years due to increased use of 
smoking and smokeless tobacco in the form of pan , gudka , ganjha. 
So Oral cavity cancers have become more common among younger 
population. But since the patients  present in locally advanced stage 
their management of cure is still challenging. Though most of them 
present in locally advanced stage , their performance status is still 
good because of their age. We are in a position to plan intense 
treatment regimen with multimodality management in order to 
achieve better local and regional control and disease free survival. 
Various Altered fractionation regimens were found to be 
useful in achieving improved local and regional control and disease 
free survival due to the delivery of increased dose to the tumour 
without increasing the complications. Though the acute toxic 
effects are known to be slightly increased, they can be very well 
managed with best supportive measures since they are not life 
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threatening. Also the late toxic effects are found to be very low 
compared to standard fractionation. This is best achieved with 
hyper fractionation regimen and concomitant boost irradiation.  
Concurrent chemotherapy along with radiation gives improved 
locoregional control with minimal increased toxicities. 
In our department also, many patients present with head and 
neck squamous cell carcinoma in a locally advanced stage. We 
prefer concurrent chemoraditherapy for most of our patients. In this 
study we opted for concomitant boost irradiation in order to achieve 
increased dose for tumour control and to shorten the treatment time 
from 6.3 weeks to 5 weeks along with low dose chemotherapy 
cisplatin and paclitaxel for radiosensitisation and increased 
therapeutic effect. 
This study included 30 patients with  squamous cell 
carcinoma of  head and neck in locally advanced stage  presented to  
our department. 
EPIDEMIOLOGICAL ASSESSMENT: 
In this study, 54% of the patients were in 5
th
 decade followed 
by 33% and 13% in the 4
th
 and 3
rd
 decade respectively. This is the 
usual presentation in most of the studies. 
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90% of the patients in this study were males while only 10% 
constitute females. This is due to increased exposure of males to 
tobacco, smoking, alcohol. Among the females, one patient had 
shrp tooth as a risk factor due to chronic irritation. 
Since this regimen has to be well tolerated patients with good 
performance status  were only included in this study. Most of the 
them were in ECOG performance status 0 and 1. 
57% of males had the habit of smoking and 30% had the habit 
of pan chewing which lead to oral cavity and oropharynx cancers. 
The most common symptom\ among the study patients was 
dysphagia (63%). Oral cavity and oropharyngeal tumours presented 
as ulcer or growth.(30%). 
Only 4 primary sites were included in order to compare the 
results of the treatment. Tumours such as nasophaynx, nasal  and 
paranasal tumours and salivary gland tumours behave differently 
and were not included in the study. Equal number of patients were 
found between oropharynx, hypopharynx and larynx malignancies 
(30%, 26%, 26%) respectively and oral cavity constitutes only 
16%of cases. 
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Among the subsites,  supraglottis and pyriform fossa 
comprised 27%of cases, followed by tonsil(20%), anterior 2/3
rd
 
tongue (13%), posterior 1/3
rd
 tongue(10%) and hard palate – only 
one patient.(3%). The subsites requiring only ipsilateral i rradiation 
such as buccal mucosa, alveolus were not included because high 
dose of radiation may increase acute effects to a larger extent.  
Most of the patients belong to tumour stage T 3, T4A (57%, 
30%), with varying nodal presentations and 13% patients had 
tumour stage T2 with nodal presentation. Among the nodal 
presentations, 54%, 33%, 13% of patients comprised of N0, N1, N2 
(a,b,c) respectively. Stage III and stage IV A  patients were only 
included in the study. Patients included in both the stages were 
almost equal 46% and 54% respectively.  Most of the tumours are 
moderately differentiated (43%) followed by well differentiated and 
poorly differentiated (30% and 27%) respectively.  
TREATMENT RESULTS ASSESSMENT 
All the 30 patients completed the treatment and available for 
analysis. Their response to treatment were assessed immediately 
after completion of the treatment clinically and after 6 weeks of 
treatment clinically, and with the help of imaging. 
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Among the study population, 83% showed complete response 
ie 25 patients and 17% showed partial response (5 patients).none of 
the patients showed static disease  or progressive disease.  
The treatment results were also analysed in detail with respect 
to further subset analysis and the response outcomes were 
individually analsed in depth. 
Among the primary sites , oropharynx, hypopharynx and 
laryngeal malignancies showed 87% – 88% complete response rates 
and only 11% - 12% showed partial response. But in case of oral 
cavity tumours, 60% had complete response and 40% had partial 
response. This may be arrtibuted to increase in the bulk of the 
disease.  
Of the subsites involved, tonsil and hard palate showed 
complete response of 100%. Next to it, pyriform fossa and 
supraglottis had complete response of 88%.  Carcinoma of tongue 
both anterior 2.3 rd and posterior 1/3
rd
 tongue showed minimal 
complete response of 50% and 66% respectively. This is due to 
increased mucositis in these patients and treatment breaks which 
lead to delay in the completion of the treatment.  
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In respect of tumour stage , T2 showed 100% complete 
response while T3 and T4 showed 88% and 66% complete response 
respectively. This is explained by the advanced nature of the 
disease with varied nodal  presentations and extent of the disease in 
advance. Similarly, patients presented with N0 and N1 nodes show 
complete response while those with N2 nodes showed only 68% of 
complete response. This is arributed to increased size of the node 
and extracapsular extension by way of matted nodal presentation.  
In view of histological differentiation, poorly differentiated 
carcinomas showed 100% complete response as expected. 
Moderately differentiated and well differentiated tumours showed 
reduction in complete response rate of 84% and 66% respectively. 
Well differentiated nature of the tumour is usually less responsive 
to radiation and it’s the reason behind the oral cavity tumours 
showing decreased complete response. But they have reduced local 
recurrences and distant metastasis. 
As usually explained, stage III tumours show increased 
complete response of 93% whreas stage IV patients showed 
complete response rate of 75%. But these results are far better when 
compared to conventional radiation, concomitant boost radiation 
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alone, and concomitant boost with cisplatin alone. This  explains the 
superiority of this study over the other similar studies.  
Other factors such as age , gender , performance status were 
also analysed  but this is not quite significant. Patients with 
performance status ECOG 0 had better outcome mainly due to the 
increased compliance of the  treatment. Similarly patients were not 
distributed equally among all age groups so its very difficult to 
interpret among them. Also most of them were males due to their 
habits and only 3 were females of which 1 patient showed partial 
response due to large bulk and extent of the disease and the 
treatment break in between due to poor tolerance. 
Regarding the treatment delay, 5 patients had 1 – 3 days of 
treatment delay and 4 patients had more than 4 days delay. Lesser 
the treatment delay, response is good. In treatment delays of 1 – 3 
days, 60% had complete response. But in more than 4 days 
treatment delay, there is only 25% response and 75% had only 
partial response.  
TOXICITY ASSESSMENT 
Acute toxicities are assessed using RTOG morbidity scoring 
criteria. Skin toxicities are found in almost all patients and usually 
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occurs from the third week of treatment. Most of them had grade 1 
reaction only and 30% patients had grade 2 and 3 reactions which 
were managed well with aloe vera and cansafe cream.  
Mucositis was an important sideeffect that caused treatment 
delay during 4
th
 and 5
th
 week of treatment. 20%  of the study 
population had grade 3 mucositis and 3% of them had Grade 4 
mucositis for whom RT was suspended till mucositis heals. They 
were best managed with antibiotics, analgesics and low dose 
steroids.  
Dry mouth was found in 72% of  patients and managed with 
saliva supplements, artificial moth sprays. Pharyngitis and 
Laryngitis were found in 80%of patient in low grades and managed 
symptomatically.  
Haematological toxicities were little more pronounced in this 
study. Only 10% of the patients needed blood transfusion during 
the treatment. 23% of patients had grade 1 and 2 leucopenia for 
which Inj G CSF was given subcutaneously for three days. RT was 
suspended for grade 3 leucopenia. There was no thrombocytopenia 
during this study. 
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Systemic toxicity were very less in this study. Only  16% of 
patients had grade 2 vomiting which were managed with IV fluids 
and antiemetics. There were no renal toxicity or cardiac toxicity in 
this study. 
There were no treatment related deaths in this study.  
Among the patients with partial response, 2 patients who had 
tumour in anterior 2/3
rd
 tongue were taken up for surgery and other 
3 patients who were not willing for morbid surgery was taken up 
for palliative chemotherapy. 
This study showed an increased tumour control rates of 
complete response 83% when compared to study conducted by 
Ghoshal showing 71% complete response rate and another study 
from our institute showing 79% complete response rate. This may 
be attributed to the addition of weekly low dose chemotherapy in 
this study. At the same time grade 3 mucositis was only 23% when 
compared to 35% in the other two studies. 
MERITS OF THE STUDY 
 Concurrent chemoradiation is the ideal management of stage 
III and stage IV head and neck SCC  and this study is based 
on it. 
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 It has shown improved local and regional control. 
 The acute toxicities were manageable. 
 There is no increase mortality or morbidity.  
 Chemotherapy – cisplatin and paclitaxel given in low doses is 
acceptable by all patients. 
 This study showed enhanced results in oropharyngeal, 
hypopharyngeal malignancies. 
DEMERITS OF THE STUDY 
 This is not a large randomozised control study and sample 
size is too small for statistical analysis. 
 All patients were treated with theratron phoenix 2D 
technique. 
 Long term followup is needed to calculate survival benefits.  
 Double armed study is recommended to compare the results.  
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FUTURE PERSPECTIVE 
Various concomitant boost trials are upcoming with 
conformal techniques also in the form of simulataneous integrated 
boost techniques. Many chemotherapy drugs are being used and 
evaluated along with radiation. Also many targetted agents such as 
EGFR inhibitors are also used along wirh radiation in the 
concurrent setting. 
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CONCLUSION 
Most of the patients with biopsy proven head and neck  
squamous cell carcinoma report to our department in a locally 
advanced stage.  This is mainly attributed to low socioeconomic 
status, poverty, illetracy. They have a fear of neglect by their own 
family and society which leads to delay in reporting to hospital at 
an advanced stage. Though many cancer awareness programmes are 
being conducted, the early case detection is still not achieved to a  
remarkable level in developing countries. Most of the patients 
present in younger age with good performance status. This becomes 
a great challenge in the management of such patients.  
This study is designed for such patients with good 
performance status with advanced disease to achieve maximum 
tumour control without causing mortality or morbidity. This study 
is succeeded with a complete response rate of 83% and partial 
response rate of 17%. 
But since there is no long term followup of this study, disease 
free survival and overall survival  cannot be calculated. Large 
randomized trials with comparison to conventional RT has been 
planned for detailed analysis. 
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Though there is significant improvement in local and regional 
control of the tumour, there is enhanced acute toxicities which can 
be well managed with best symptomatic care. Therefore selection 
of patients is very important in this study in order to complete the 
treatment protocol within the stipulated time. The main advantage 
is the reduction of treatment duration to 5 weeks which is very 
essential in centers with patients overload. 
Thus concomitant boost irradiation with weekly low dose 
chemotherapy is a feasible option with good locoregional control 
and manageable toxicities in patients with good performance status.  
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APPENDIX – III 
RTOG ACUTE RADIATION MORBIDITY CRITERIA 
Site Grade0 Grade1 Grade2 Grade3 Grade 4 
SKIN 
No 
change 
over 
baseline 
Follicular, faint 
or dull erythema/ 
epilation/dry 
desquamation/ 
decreased 
sweating  
 
Tender or 
bright 
erythema, 
patchy moist 
desquamation/ 
moderate 
edema  
Confluent, 
moist 
desquamation 
other than 
skin folds, 
pitting edema 
Ulceration, 
hemorrhage, 
necrosis  
 
Mucous 
Membrane  
 
No 
change 
over 
baseline  
 
Injection/ may 
experience mild 
pain not 
requiring 
analgesic  
 
Patchy 
mucositis 
which may 
produce an 
inflammatory 
serosanguinitis 
discharge/ 
may 
experience 
moderate pain 
requiring 
analgesia  
Confluent 
fibrinous 
mucositis/ 
may include 
severe pain 
requiring 
narcotic  
 
Ulceration, 
hemorrhage 
or necrosis  
 
Salivary 
Gland  
 
No 
change 
over 
baseline  
 
Mild mouth 
dryness/ slightly 
thickened saliva/ 
may have 
slightly altered 
taste such as 
metallic taste/ 
these changes not 
reflected in 
alteration in 
baseline feeding 
behavior, such as 
increased use of 
liquids with 
meals 
Moderate to 
complete 
dryness/ thick, 
sticky saliva/ 
markedly 
altered taste  
 
 Acute 
salivary 
gland 
necrosis  
 
 21 
Site Grade0 Grade1 Grade2 Grade3 Grade 4 
Pharynx 
& 
Esophagus  
 
No 
change 
over 
baseline  
 
Mild dysphagia 
or odynophagia/ 
may require 
topical anesthetic 
or non-narcotic 
analgesics/ may 
require soft diet  
 
Moderate 
dysphagia or 
odynophagia/ 
may require 
narcotic 
analgesics/ 
may require 
puree or liquid 
diet  
 
Severe 
dysphagia or 
odynophagia 
with 
dehydration 
or weight 
loss(>15% 
from pre-
treatment 
baseline) 
requiring  
N-G feeding 
tube, I.V. 
fluids or 
hyper 
alimentation  
Complete 
obstruction, 
ulceration, 
perforation, 
fistula  
 
Laryngitis  
 
No 
change 
over 
baseline  
 
Mild or 
intermittent 
hoarseness/cough 
not requiring 
antitussive/ 
erythema of 
mucosa  
 
Persistent 
hoarseness but 
able to 
vocalize/ 
referred ear 
pain, sore 
throat, patchy 
fibrinous 
exudate or 
mild arytenoid 
edema not 
requiring 
narcotic/ 
antitussive  
 
Whispered 
speech, throat 
pain or 
referred ear 
pain 
requiring 
narcotic/ 
confluent 
fibrinous 
exudate, 
marked 
arytenoid 
edema  
 
Marked 
dyspnea, 
stridor or 
hemoptysis 
with 
tracheostomy 
or intubation 
necessary  
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APPENDIX – IV 
HEMATOLOGIC TOXICITY 
Grade 0 1 2 3 4 
HEMATOLOGIC 
WBC (X 1000)  
 
>=4.0 
 
3.0 - 
<4.0 
 
2.0 - 
<3.0 
 
1.0 - 
<2.0 
 
<1.0 
PLATELETS (X 
1000)  
 
>=100 
 
75 - 
<100 
 
50 - 
<75 
 
25 - 
<50 
 
<25 or 
spontaneous 
bleeding 
NEUTROPHILS  
 
>=1.9 
 
1.5 - 
<1.9 
 
1.0 - 
<1.5 
 
0.5 - 
<1.0 
 
<0.5 or 
sepsis 
 
HEMOGLOBIN 
(GM %)  
>11 
 
11-
9.5 
 
<9.5 
- 7.5 
 
<7.5 
- 5.0 
 
- 
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APPENDIX - V  
COMMON TERMINOLOGY CRITERIA FOR 
ADVERSE EVENTS CTCAE VERSION 4 
GRADE 1 2 3 4 
Nausea Loss of 
appetite 
without 
alteration 
in eating 
habits  
 
Oral intake 
decreased 
without 
significant 
weight loss, 
dehydration 
or 
malnutrition  
Inadequate oral 
caloric or fluid 
intake, tube feeding, 
TPN, or 
hospitalization 
indicated  
 
- 
Vomiting  
 
1-2 
episodes  
(separated 
by 5 
minutes) 
in 24 hrs 
3-5 
episodes 
(separated 
by 5 
minutes) in 
24 hrs 
>/=6 episodes 
(separated by 5 
minutes) in 24 
hrs,tubefeeding,TPN 
or hospitalization 
indicated 
Life-
threatening 
consequences, 
urgent 
intervention 
indicated  
 
Diarrhea Increase 
of <4 
stools per 
day 
over 
baseline; 
mild 
increase 
in 
ostomy 
output 
compared 
to 
baseline 
Increase of 
4 -6 stools 
per da 
over 
baseline; 
moderate 
increase in 
ostomy 
output 
compared to 
baseline 
Increase of =7 
stools per day 
over baseline; 
incontinence; 
hospitalization 
indicated;severe 
increase in ostomy 
output compared to 
baseline; limiting 
self care ADL 
Life-
threatening 
consequences; 
urgent 
intervention 
indicated 
 
ANNEXURE – 1 
INFORMATION TO PARTICIPANTS 
Title: “CONCOMITANT  BOOST  IRRADIATION  WITH  WEEKLY  
LOW DOSE CHEMOTHERAPY  IN  LOCALLY  ADVANCED  
SQUAMOUS CELL CARCINOMA OF  HEAD AND NECK” 
Name of Participant: 
Name of the Principal(co – investigator) :DR.S.SELVALAKSHMI 
Name of the institution : Department of radiotherapy, RGGGH, MMC. 
 
You are invited to take part in this research/ study/procedures/tests. The 
information in this document is meant to help you decide whether or not to take 
part. Please feel free to ask if you have any queries or concerns. 
What is the purpose of research? 
 65% patients with head and neck tumors present with locally advanced  
disease. Concurrent chemoradiotherapy is a treatment program for 
locoregionally advanced squamous cell carcinomas of the head and neck 
(SCCHN), with established benefits in both organ preservation and 
survival. Concomitant Boost means delivering two fractions of radiation 
daily either in the beginning or in the end of treatment in order to prevent 
accelerated repopulation in head and neck cancers. The boost is given 
only to the primary tumour site and the involved nodes. Weekly cisplatin 
is a more acceptable regimen than three weekly cisplatin. Paclitaxel 
causes cell cycle arrest at G2M phase which is a radiosensitive phase and 
thereby potentiating radiation.  Radiotherapy will be delivered by 
opposing lateral fields with a telecobalt machine using concomitant boost 
technique of  45gy/1.8gyper# /25#  -  5 weeks and 22.5gy/ 1.5gy per# 
/15#  given as a boost only to small field including primary and involved 
node at an interval of 6 hrs during last 3 weeks of treatment. Patients are 
given a break on Saturday and Sunday. Weekly Cisplatin and Weekly 
Paclitaxel chemotherapy is given every Monday before radiation. Entire 
treatment is to be completed in 5 weeks time .Primary and gross 
adenopathy receive 67.5GY. 
 We want to test the efficacy and safety of  “concomitant boost 
radiotherapy with weekly low dose chemotherapy “ .We have obtained 
permission from the Institutional Ethics Committee.  
The study design 
Single arm prospective study 
Study Procedures 
The study involves evaluation of Locally advanced squamous cell 
carcinoma of the head and neck with concomitant radiotherapy and chemo in 
the form of low dose weekly inj.cisplatin and inj paclitaxel. Every week before 
chemotherapy, the study physician will examine you. Some [blood / urine 
/clinical examination other] tests will be carried out at each visit. [… … ml of 
blood will be collected at each visit. Blood collection involves prick with a 
needle and syringe.] These tests are essential to monitor your condition, and to 
assess the safety and efficacy of the treatment given to you. 
In addition, if you notice any physical or mental change(s), you must 
contact the persons listed at the end of the document.  
You may have to come to the hospital (study site) for examination and 
investigations apart from your scheduled visits, if required.  
 
Possible benefits to other people  
 
The results of the research may provide benefits to the society in terms of 
advancement of medical knowledge and/or therapeutic benefit to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your 
medical information (personal details, results of physical examinations, 
investigations, and your medical history). By signing this document, you will be 
allowing the research team investigators, other study personnel, sponsors, 
Institutional Ethics Committee and any person or agency required by law like 
the Drug Controller General of India to view your data, if required. 
The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your 
medical care or your relationship with the investigator or the institution. You 
will be taken care of and you will not lose any benefits to which you are 
entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the 
right to withdraw from this study at any time during the course of the study 
without giving any reasons. However, it is advisable that you talk to the 
research team prior to stopping the treatment/discontinuing of procedures etc. 
 
Signature of Investigator                                                  Signature of participant 
Date :         Date: 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE – II 
INFORMED CONSENT FORM 
TITLE OF THE STUDY “CONCOMITANT BOOST IRRADIATION WITH WEEKLY LOW 
DOSE CHEMOTHERAPY IN LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA 
OF HEAD AND NECK” 
NAME OF THE PARTICIPANT: 
NAME OF THE PRINCIPAL (Co – Investigator) : DR.S.SELVALAKSHMI., 
NAME OF THE INSTITUTION: MADRAS MEDICAL COLLEGE 
 
_____________________________ have read the information in this form (or it has been read to me). 
I was free to ask any questions and they have been answered. I am over 18 years of age and, 
exercising my free power of choice, hereby give my consent to be included as a participant in 
“CONCOMITANT BOOST IRRADIATION WITH WEEKLY LOW DOSE 
CHEMOTHERAPY IN LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF 
HEAD AND NECK” 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have taken in the past 12 
months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study.* 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I suffer 
unusual symptoms. * 
8. I have not participated in any research study within the past  12 month(s). * 
9. I agree to undergo complete blood count, renal and liver function test, chest x ray, CT scan   of the 
head and  neck 
10. I am aware of the fact that I can opt out of the study at any time without having to give any reason 
and this will not affect my future treatment in this hospital. * 
11. I am also aware that the investigator may terminate my participation in the study at any time, for 
any reason, without my consent. * 
12. I hereby give permission to the investigators to release the information obtained from me as result 
of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and IEC. I 
understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. By signing 
this consent form I attest that the information given in this document has been clearly explained to me 
and understood by me, I will be given a copy of this consent document 
Name and signature / thumb impression of the participant (or legal representative if participant 
incompetent) 
 
Signature of Investigator                                                  Signature of participant 
Date :         Date: 
ANNEXURE - III 
Bµõ´a] J¨¦uÀ £iÁ® 
Bµõ´a] uø»¨¦ 
uø» ©ØÖ® PÊzx £Sv°À EÒÍ ¬ØÔ¯ a÷Põö©Íì ö\À ÁøP ¦ØÖ÷{õ´US ©õØÖ 
PvºÃa_ ]Qmø\²® (Cøn¢u FUP PvºÃa_ ]Qmø\ ¬øÓ) AuÝhß Áõµ® J¸ 
¬øÓ AÍÄ SøÓUP¨£mh ÷Áv ]Qmø\²® öPõkzuÀ 
 
ö£¯º   :      ÷uv    : 
Á¯x  :      EÒ ÷{õ¯õÎ Gs  : 
£õÀ  :      Bµõ´a] ÷\ºUøP Gs : 
 
 C¢u Bµõ´a]°ß ÂÁµ[PÐ® Auß ÷{õUP¬® ¬Êø©¯õP GÚUS öuÎÁõP 
ÂÍUP¨£mhx. 
 GÚUS ÂÍUP¨£mh Âå¯[PøÍ ¦¶¢xUöPõsk {õß GÚx \®©uzøu 
öu¶ÂUQ÷Óß. 
 GÚUS ¦ØÖ÷{õ´ C¸US® £Sv°À PvºÃa_ ]Qaø\²® AuÝhß  Áõµ® J¸ 
¬øÓ ]ì¤Íõiß ©ØÖ® ÷£U¼÷hUéÀ ©¸¢x® GkzxU öPõÒÍ \®©u®. 
 C¢u Bµõ´a]°À ¤Ó¶ß |º£¢uªßÔ Gß ö\õ¢u Â¸¨£zvß÷£¶À {õß £[S 
ö£ÖQß÷Óß. C¢u Bµõ´a]°À C¸¢x {õß G¢÷{µ¬® ¤ß Áõ[P»õ® Gß£øu²® 
AuÚõÀ G¢u £õv¨¦® HØ£hõx Gß£øu²® {õß ¦¶¢xöPõs÷hß. 
 {õß uø» ©ØÖ® PÊzx £Sv°À ¬ØÔ¯ ¦ØÖ÷{õ´ SÔzu C¢u B´ÄUPõÚ 
ÂÁµ[PÒ öPõsh uPÁÀ uõøÍ¨ ö£ØÖUöPõs÷hß. 
 GÚUS C¢u Bµõ´a]°ß£i PvºÃa_ ]Qaø\ ©ØÖ® ¦ØÖ÷{õ´ ©¸¢xPÒ 
ö£ØÖUöPõÒÍ \®©u®. C¢u Bµõ´a]US ÷uøÁ¯õÚ ¤Ó £¶÷\õuøÚPÒ 
ö\´xUöPõÒÍ \®©u®. 
 {õß GßÝøh¯ _¯ |øÚÄhÝ® ©ØÖ® ¬Ê _u¢vµzxhÝ® C¢u ©¸zxÁ 
Bµõ´a]°À GßøÚ ÷\ºzxUöPõÒÍ \®©u® öu¶ÂUQ÷Óß. 
 
 
 
 
{õÒ : 
 
Ch® :           øPö¯õ¨£® 
MŒî jftš jhŸ 
MŒî jiy¥ò 
jiy k‰W« fG¤J¥gFâÆš cŸs K‰¿a °Fthk° brš tif ò‰WnehŒ¡F kh‰W 
fâ®å¢R á»¢irí« (ïizªj C¡f fâ®å¢R á»¢ir Kiw) mjDl‹ thu« xUKiw 
msî Fiw¡f¥g£l ntâ á»¢irí« bfhL¤jš 
MŒths® : 
g¤nf‰ghs® : 
ïªj MŒî uhé› fhªâ muR bghJ kU¤JtkidÆš eilbgw cŸsJ. Ú¤fS« 
ïªj MŒÇš g¤nf‰f eh¤fŸ ÇU«ò»nwh«. ïâYŸs jftÈ‹ mo¥gilÆš ïªj 
MŒÇš g¤nf‰gjh mšyJ nt©lhkh v‹W Ú¤fŸ Koî brŒJ bfhŸsyh«. 
c¤fsJ rªnjf¤fis v¤fËl« nf£L Ãt®¤â brŒJ bfhŸsyh«. 
ïªj MŒÇ‹ neh¡f«: 
kh¿tU« bghUshjhu fhuÂfŸ k‰W« thœ¡ifKiwÆ‹ fhuzkhf jiy k‰W« 
fG¤J¥gFâ ò‰WnehÆdhš ghâ¡f¥g£lt®fË‹ v©Â¡if rÛgfhykhf 
mâfÇ¤J¡bfh©nl tU»wJ. 
bgU«ghyhndh® ïªj nehŒ K‰¿a ÃiyÆnyna kU¤Jtkid¡F tU»‹wd®. 
mjdhš KGtJ« Fz¥gL¤j¡Toa it¤âa Kiwfis ga‹gL¤J« thŒ¥ig 
ïH¡»‹wd®. mjdhš nehŒ¡F¿ jÅ¥ò it¤âa Kiwfis k£Lnk ga‹gL¤J« 
Ãiy¡F Msh»‹wd®. ï›tifahd it¤âa¤âš gytif cŸsd. ïªj MŒÇš 
ga‹gL¤J« it¤âa KiwÆ‹ _y« áwªj nehŒ¡F¿ jÅ¥igí« Fiwthd 
ã‹Çisîfisí« bgU« tifÆš tÊ brŒtnj v¤fŸ neh¡fkhF«. 
MŒÇ‹ brašKiw: 
nehahËfŸ ïu¤j¥ gÆnrhjid, Kf« k‰W« fG¤J¥gFâ á.o.°nf‹, beŠR¥gFâ 
v¡°-nu, gš R¤j« k‰W« ghJfh¥ò, òif¥gH¡f¤ij ifÇl Mnyhrid 
KjÈat‰iw nk‰bfhŸs nt©L«. ïit mid¤J« tH¡fkhf všyh 
ò‰WnehahËfËlK« nehÆ‹ Ãiyia m¿a nk‰bfhŸgitna. nehahËfS¡F 
âdK« ïUKiw 5 eh£fŸ 6 thu¤fS¡F nehŒF¿ jÅ¥ò fâ®å¢Rl‹ thu« 
xUKiw á°ãsh£o‹, gh¡Èlh¡áš vD« kUªJfŸ brY¤j¥gL«. 
MW thu¤fŸ fÊ¤J nehÆ‹ Ãiyia m¿a á.o.°nf‹ k‰W« clš gÆnrhjid 
brŒa¥gL«. ïªj gÆnrhjidfŸ ï›tifahd it¤âa¤â‹ ÇisîfŸ k‰W« 
ga‹fis m¿a mtáa«.  
MŒÇdhš V‰gL« e‹ikfŸ 
áwªj nehŒ¡F¿ jÅ¥ò«, Fiwthd ã‹ÇisîfS« »il¡f mâf thŒ¥òfŸ 
cŸsd. 
MŒÇdhš V‰gL« ÔikfŸ 
tH¡fkhd fâ®å¢RfËš tU« ÇisîfisÇl mâf« VJÄšiy. 
MŒÇdhš ãwU¡F V‰gL« e‹ikfŸ: 
ïªj MŒÇš fyªJbfhŸtj‹ _ykhf Ú¤fŸ nehÆ‹ j‹ikÆš K‹nd‰w« 
bgwyh«. nkY« tU¤fhy¤âš ãw nehahËfS« ga‹bgw ïªj MŒî cjÇahf 
mikí«. 
kU¤Jt á»¢irÆ‹ jftšfŸ F¿¤j Çtu¤fŸ: 
c¤fŸ kU¤Jt á»¢ir F¿¤j jftšfŸ ufáakhf ghJfh¡f¥gL«. 
Ú§fS« ïªj MuhŒ¢áÆš g¤nf‰f eh¤fŸ ÇU«ò»nwh«. ïªj MuhŒ¢áÆš 
c¤fS¡F gÆnrhjidfŸ brŒJ mj‹ jftšfis MuhŒnth«. mjdhš j¤fsJ 
nehÆ‹ MŒt¿¡ifnah mšyJ á»¢irnah ghâ¥ò V‰glhJ v‹gijí« 
bjÆÇ¤J¡bfhŸ»nwh«. 
Koîfis mšyJ fU¤Jfis btËÆL«nghnjh mšyJ MuhŒ¢áÆ‹ nghnjh 
j¤fsJ bgaiunah mšyJ milahs¤fisnah btËÆl kh£nlh« v‹gijí« 
bjÆÇ¤J¡ bfhŸ»nwh«.  
ïªj MuhŒ¢áÆš g¤nf‰gJ j¤fSila ÇU¥g¤â‹ ngÆš jh‹ ïU¡»wJ. nkY« 
Ú¤fŸ vªneuK« ïªj MuhŒ¢áÆÈUªJ ã‹th¤fyh« v‹gijí« bjÆÇ¤J¡ 
bfhŸ»nwh«.  
ïªj áw¥ò á»¢irÆ‹ Koîfis MuhŒ¢áÆ‹nghJ mšyJ MuhŒ¢áÆ‹ KoÇ‹ 
nghJ j¤fS¡F m¿Ç¡f¥gL« v‹gijí« bjÆÇ¤J¡ bfhŸ»nwh«.  
 
 
MuhŒ¢áahs® ifbah¥g«   g¤nf‰ghs® ifbah¥g« 
ehŸ  : 
ïl« : 
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